Inhibition of p38 MAP kinase by utilizing a novel alloste

Nature Structural Biology

9, 268-272

DOI: 10.1038/nsb770

Citation Report

#	Article	IF	Citations
2	In the Cellular Garden of Forking Paths: How p38 MAPKs Signal for Downstream Assistance. Biological Chemistry, 2002, 383, 1519-36.	1.2	146
3	Chapter 18. Inhibitors of p38Î± MAP kinase. Annual Reports in Medicinal Chemistry, 2002, 37, 177-186.	0.5	18
4	Anti-Inflammatory Effects of a p38 Mitogen-Activated Protein Kinase Inhibitor During Human Endotoxemia. Journal of Immunology, 2002, 168, 4070-4077.	0.4	235
5	Latest developments in crystallography and structure-based design of protein kinase inhibitors as drug candidates. Current Opinion in Pharmacology, 2002, 2, 567-573.	1.7	27
6	Chemical microarrays, fragment diversity, label-free imaging by plasmon resonance?a chemical genomics approach. Journal of Cellular Biochemistry, 2002, 87, 79-84.	1.2	27
7	Synthesis and pharmacological characterization of a potent, orally active p38 kinase inhibitor. Bioorganic and Medicinal Chemistry Letters, 2002, 12, 1559-1562.	1.0	27
9	Pyrazole Urea-Based Inhibitors of p38 MAP Kinase:Â From Lead Compound to Clinical Candidate. Journal of Medicinal Chemistry, 2002, 45, 2994-3008.	2.9	346
10	Molecular therapies in Crohns disease: coming of age. International Journal of Colorectal Disease, 2002, 17, 285-286.	1.0	0
11	Protein structure: discovering selective protein kinase inhibitors. Targets, 2003, 2, 101-108.	0.3	9
12	Mechanistic considerations in high-throughput screening. Analytical Biochemistry, 2003, 320, 1-12.	1.1	151
13	N-Phenyl-N-purin-6-yl ureas: The design and synthesis of p38Î± MAP kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 1191-1194.	1.0	36
14	The kinetics of binding to p38MAP kinase by analogues of BIRB 796. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 3101-3104.	1.0	105
15	Structureâ€“activity studies of a series of dipyrazolo[3,4- b :3â€²,4â€²- d]pyridin-3-ones binding to the immune regulatory protein B7.1. Bioorganic and Medicinal Chemistry, 2003, 11, 2991-3013.	1.4	39
16	Lead compounds discovered from libraries: Part 2. Current Opinion in Chemical Biology, 2003, 7, 308-325.	2.8	77
17	Mitogen-activated protein kinases in chronic intestinal inflammation - targeting ancient pathways to treat modern diseases. Alimentary Pharmacology and Therapeutics, 2003, 18, 17-32.	1.9	25
18	Structural basis for p38Î± MAP kinase quinazolinone and pyridol-pyrimidine inhibitor specificity. Nature Structural and Molecular Biology, 2003, 10, 764-769.	3.6	194
19	Therapeutic strategies for rheumatoid arthritis. Nature Reviews Drug Discovery, 2003, 2, 473-488.	21.5	727
20	Implications of protein flexibility for drug discovery. Nature Reviews Drug Discovery, 2003, 2, 527-541.	21.5	640

#	Article	IF	Citations
21	p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nature Reviews Drug Discovery, 2003, 2, 717-726.	21.5	1,076
22	Structureâ^'Activity Relationships of the p38Î± MAP Kinase Inhibitor 1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)naph- thalen-1-yl]urea (BIRB 796). Journal of Medicinal Chemistry, 2003, 46, 4676-4686.	2.9	110
23	Kinases, Homology Models, and High Throughput Docking. Journal of Medicinal Chemistry, 2003, 46, 4638-4647.	2.9	129
24	Thermal Denaturation:â€‰ A Method to Rank Slow Binding, High-Affinity P38Î± MAP Kinase Inhibitors. Journal of Medicinal Chemistry, 2003, 46, 4669-4675.	2.9	52
25	Downstream DNA Sequence Effects on Transcription Elongation. Journal of Biological Chemistry, 2003, 278, 35597-35608.	1.6	57
26	Organische Chemie 2002. Nachrichten Aus Der Chemie, 2003, 51, 286-315.	0.0	3
27	Chapter 15. Emerging opportunities for the treatment of inflammatory bowel disease. Annual Reports in Medicinal Chemistry, 2003, 38, 141-152.	0.5	0
28	Inhibition of coagulation, fibrinolysis, and endothelial cell activation by a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. Blood, 2003, 101, 4446-4448.	0.6	74
29	Allosteric Modulation of G Protein-Coupled Receptors. Current Pharmaceutical Design, 2004, 10, 2003-2013.	0.9	84
30	Targeting MAPK Signalling: Prometheus Fire or Pandoras Box?. Current Pharmaceutical Design, 2004, 10, 1885-1905.	0.9	54
31	Virtual Screening for Kinase Targets. Current Medicinal Chemistry, 2004, 11, 693-707.	1.2	70
32	High-Throughput Structural Biology in Drug Discovery: Protein Kinases. Current Pharmaceutical Design, 2004, 10, 1069-1082.	0.9	46
33	Nuclear Export Inhibitors and Kinase Inhibitors Identified Using a MAPK-Activated Protein Kinase 2 RedistributionÂ®Screen. Assay and Drug Development Technologies, 2004, 2, 7-20.	0.6	54
34	Two Simple and Generic Antibody-Independent Kinase Assays: Comparison of a Bioluminescent and a Microfluidic Assay Format. Journal of Biomolecular Screening, 2004, 9, 409-416.	2.6	30
35	Development of a Fluorescence Polarization Bead-Based Coupled Assay to Target Different Activity/Conformation States of a Protein Kinase. Journal of Biomolecular Screening, 2004, 9, 309-321.	2.6	12
36	Inhibitors of Protein Kinase Signaling Pathways. Circulation, 2004, 109, 1196-1205.	1.6	124
37	The p38 mitogen-activated protein kinase (MAPK) pathway mediates induction of the tissue factor gene in monocytes stimulated with human monoclonal anti-Â2Glycoprotein I antibodies. International Immunology, 2004, 16, 1633-1641.	1.8	115
38	Biologics in inflammatory bowel disease: how much progress have we made?. Gut, 2004, 53, 1366-1373.	6.1	55

#	Article	IF	Citations
39	Allosteric inhibition of protein tyrosine phosphatase 1B. Nature Structural and Molecular Biology, 2004, 11, 730-737.	3.6	441
40	Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nature Structural and Molecular Biology, 2004, 11, 1192-1197.	3.6	575
41	Crystal Structure of the Carboxyltransferase Domain of Acetyl-Coenzyme A Carboxylase in Complex with CP-640186. Structure, 2004, 12, 1683-1691.	1.6	64
42	Searching for new allosteric sites in enzymes. Current Opinion in Structural Biology, 2004, 14, 706-715.	2.6	293
43	Sequence and structural analysis of kinase ATP pocket residues. Il Farmaco, 2004, 59, 759-765.	0.9	87
44	P38 Mitogen Activated Protein Kinase Is Involved in the Downregulation of Granulocyte CXC Chemokine Receptors 1 and 2 During Human Endotoxemia. Journal of Clinical Immunology, 2004, 24, 37-41.	2.0	14
45	Multiple Active Site Corrections for Docking and Virtual Screening. Journal of Medicinal Chemistry, 2004, 47, 80-89.	2.9	112
46	Protein Kinase Inhibitors: Insights into Drug Design from Structure. Science, 2004, 303, 1800-1805.	6.0	1,164
47	A Biacore biosensor method for detailed kinetic binding analysis of small molecule inhibitors of p38Î± mitogen-activated protein kinase. Analytical Biochemistry, 2004, 325, 126-136.	1.1	64
48	Isoindolinone ureas: a novel class of KDR kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 4505-4509.	1.0	31
49	Is allostery an intrinsic property of all dynamic proteins?. Proteins: Structure, Function and Bioinformatics, 2004, 57, 433-443.	1.5	779
50	Conformation-dependent intermolecular interaction energies of the triphosphate anion with divalent metal cations. Application to the ATP-binding site of a binuclear bacterial enzyme. A parallel quantum chemical and polarizable molecular mechanics investigation. Journal of Computational Chemistry, 2004, 25, 160-168.	1.5	19
51	Synthesis of deuterium, tritium, and carbon-14 labeled BIRB 796, a p38 MAP kinase inhibitor. Journal of Labelled Compounds and Radiopharmaceuticals, 2004, 47, 847-856.	0.5	1
52	Novel, potent and selective anilinoquinazoline and anilinopyrimidine inhibitors of p38 MAP kinase. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 5389-5394.	1.0	62
53	Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2004, 1697, 17-27.	1.1	123
54	Kinomicsâ€"structural biology and chemogenomics of kinase inhibitors and targets. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2004, 1697, 243-257.	1.1	168
55	Kinase Targets and Inhibitors for the Treatment of Airway Inflammatory Diseases. BioDrugs, 2004, 18, 167-180.	2.2	14
56	A Novel Mode of Gleevec Binding Is Revealed by the Structure of Spleen Tyrosine Kinase. Journal of Biological Chemistry, 2004, 279, 55827-55832.	1.6	179

#	Article	IF	Citations
57	Discovery and Characterization of a Substrate Selective p38Î± Inhibitor. Biochemistry, 2004, 43, 11658-11671.	1.2	112
58	Tethering: Fragment-Based Drug Discovery. Annual Review of Biophysics and Biomolecular Structure, 2004, 33, 199-223.	18.3	375
59	General Model for Estimation of the Inhibition of Protein Kinases Using Monte Carlo Simulations. Journal of Medicinal Chemistry, 2004, 47, 2534-2549.	2.9	48
60	Glide:â€‰ A New Approach for Rapid, Accurate Docking and Scoring. 2. Enrichment Factors in Database Screening. Journal of Medicinal Chemistry, 2004, 47, 1750-1759.	2.9	3,982
61	The p38 MAP kinase pathway as a therapeutic target in inflammatory disease. Current Opinion in Pharmacology, 2004, 4, 372-377.	1.7	382
62	Improved expression, purification, and crystallization of p38Î± MAP kinase. Protein Expression and Purification, 2004, 37, 154-161.	0.6	40
63	Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF. Cell, 2004, 116, 855-867.	13.5	2,479
64	Catalysis and Function of the p38Î±Â·MK2a Signaling Complex. Biochemistry, 2004, 43, 9950-9960.	1.2	47
65	Inhibitors of PKA and Related Protein Kinases. , 2005, , 85-124.		3
66	Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors. Biochemical Journal, 2005, 385, 399-408.	1.7	382
67	Crystallography for protein kinase drug design: PKA and SRC case studies. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2005, 1754, 38-49.	1.1	12
68	Following in vitro activation of mitogen-activated protein kinases by mass spectrometry and tryptic peptide analysis: purifying fully activated p38 mitogen-activated protein kinase Î±. Analytical Biochemistry, 2005, 336, 1-10.	1.1	11
69	Time-resolved Forster resonance energy transfer assays for the binding of nucleotide and protein substrates to p38Î± protein kinase. Analytical Biochemistry, 2005, 343, 76-83.	1.1	22
70	Ligand binding affinity determined by temperature-dependent circular dichroism: Cyclin-dependent kinase 2 inhibitors. Analytical Biochemistry, 2005, 345, 187-197.	1.1	37
71	Features of Selective Kinase Inhibitors. Chemistry and Biology, 2005, 12, 621-637.	6.2	582
72	Protein kinases as targets for antimalarial intervention: Kinomics, structure-based design, transmission-blockade, and targeting host cell enzymes. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2005, 1754, 132-150.	1.1	78
73	HierS:Â Hierarchical Scaffold Clustering Using Topological Chemical Graphs. Journal of Medicinal Chemistry, 2005, 48, 3182-3193.	2.9	94
74	Orthogonal Chemical Genetic Approaches for Unraveling Signaling Pathways. IUBMB Life, 2005, 57, 397-405.	1.5	8

#	Article	IF	Citations
75	Prospective Exploration of Synthetically Feasible, Medicinally Relevant Chemical Space. Journal of Chemical Information and Modeling, 2005, 45, 239-248.	2.5	35
76	A small moleculeâ€“kinase interaction map for clinical kinase inhibitors. Nature Biotechnology, 2005, 23, 329-336.	9.4	1,785
77	Structure and function of Polo-like kinases. Oncogene, 2005, 24, 248-259.	2.6	283
78	Kinetic mechanism for p38 MAP kinase alpha. A partial rapid-equilibrium random-order ternary-complex mechanism for the phosphorylation of a protein substrate. FEBS Journal, 2005, 272, 4631-4645.	2.2	21
79	Kinomics: characterizing the therapeutically validated kinase space. Drug Discovery Today, 2005, 10, 839-846.	3.2	164
80	Crystal Structures of the Mnk2 Kinase Domain Reveal an Inhibitory Conformation and a Zinc Binding Site. Structure, 2005, 13, 1559-1568.	1.6	57
81	Structure-Based Drug Discovery. , 2005, , 295-321.		1
82	Classifying â€œKinase Inhibitor-Likenessâ€•by Using Machine-Learning Methods. ChemBioChem, 2005, 6, 558-566.	1.3	46
83	Strategies for the NMR-Based Identification and Optimization of Allosteric Protein Kinase Inhibitors. ChemBioChem, 2005, 6, 1607-1610.	1.3	26
84	Protein Kinase Inhibitors for the Treatment of Disease: The Promise and the Problems. , 2005, , 1-7.		0
85	Strategies for the Design of Potent and Selective Kinase Inhibitors. Current Pharmaceutical Design, 2005, 11, 1845-1863.	0.9	58
86	Pharmacological Potential of p38 MAPK Inhibitors. Handbook of Experimental Pharmacology, 2005, , 65-83.	0.9	4
87	BIRB796 Inhibits All p38 MAPK Isoforms in Vitro and in Vivo. Journal of Biological Chemistry, 2005, 280, 19472-19479.	1.6	265
88	The Transcription Factor NF-ÎºB as Drug Target. Progress in Medicinal Chemistry, 2005, 43, 137-188.	4.1	10
89	Disabling TNF receptor signaling by induced conformational perturbation of tryptophan-107. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 10970-10975.	3.3	35
90	Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 11011-11016.	3.3	529
91	Role of the p38 Mitogen-Activated Protein Kinase Pathway in Cytokine-Mediated Hematopoietic Suppression in Myelodysplastic Syndromes. Cancer Research, 2005, 65, 9029-9037.	0.4	60
92	Pyrazolo[1,5-a]pyridines as p38 Kinase Inhibitors. Organic Letters, 2005, 7, 4753-4756.	2.4	87

#	Article	IF	Citations
93	Design of Potent and Selective 2-Aminobenzimidazole-Based p38Î± MAP Kinase Inhibitors with Excellent in Vivo Efficacy. Journal of Medicinal Chemistry, 2005, 48, 2270-2273.	2.9	49
94	Synthetic Studies toward Aryl-(4-aryl-4H-[1,2,4]triazole-3-yl)-amine from 1,3-Diarylthiourea as Urea Mimetics. Journal of Organic Chemistry, 2005, 70, 6362-6368.	1.7	41
95	Second-generation kinase inhibitors. Expert Opinion on Therapeutic Targets, 2005, 9, 975-993.	1.5	55
96	Prevention of MKK6-Dependent Activation by Binding to p38Î± MAP Kinaseâ€¡. Biochemistry, 2005, 44, 16475-16490.	1.2	91
97	Global Kinase Screening. Applications of Frontal Affinity Chromatography Coupled to Mass Spectrometry in Drug Discovery. Analytical Chemistry, 2005, 77, 1268-1274.	3.2	51
98	Inhibition of the Tyrosine Kinase, Syk, Analyzed by Stepwise Nonparametric Regression. Journal of Chemical Information and Modeling, 2005, 45, 768-776.	2.5	4
99	High Affinity Targets of Protein Kinase Inhibitors Have Similar Residues at the Positions Energetically Important for Binding. Journal of Molecular Biology, 2005, 352, 1134-1156.	2.0	42
100	Inhibition of the cell cycle with chemical inhibitors: A targeted approach. Seminars in Cell and Developmental Biology, 2005, 16, 369-381.	2.3	13
102	New Therapeutics in Rheumatoid Arthritis. Rheumatic Disease Clinics of North America, 2006, 32, 57-74.	0.8	15
103	Oral p38 Mitogen-Activated Protein Kinase Inhibition With BIRB 796 for Active Crohnâ€™s Disease: A Randomized, Double-Blind, Placebo-Controlled Trial. Clinical Gastroenterology and Hepatology, 2006, 4, 325-334.	2.4	165
104	Design, Synthesis, and Biological Evaluation of Phenylamino-Substituted 6,11-Dihydro-dibenzo[b,e]oxepin-11-ones and Dibenzo[a,d]cycloheptan-5-ones:Â Novel p38 MAP Kinase Inhibitors. Journal of Medicinal Chemistry, 2006, 49, 7912-7915.	2.9	40
105	Diarylureas are small-molecule inhibitors of insulin-like growth factor I receptor signaling and breast cancer cell growth. Molecular Cancer Therapeutics, 2006, 5, 1079-1086.	1.9	78
106	N-(5-Chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a Novel, Highly Selective, Orally Available, Dual-Specific c-Src/Abl Kinase Inhibitorâ€. Journal of Medicinal Chemistry, 2006, 49, 6465-6488.	2.9	320
107	Microwave-assisted synthesis of N-pyrazole ureas and the p38? inhibitor BIRB 796 for study into accelerated cell ageing. Organic and Biomolecular Chemistry, 2006, 4, 4158.	1.5	77
108	Benchmarking Sets for Molecular Docking. Journal of Medicinal Chemistry, 2006, 49, 6789-6801.	2.9	1,184
109	Development of Quantitative Structureâ^'Binding Affinity Relationship Models Based on Novel Geometrical Chemical Descriptors of the Proteinâ^'Ligand Interfaces. Journal of Medicinal Chemistry, 2006, 49, 2713-2724.	2.9	99
110	Structure-Based Identification of Small Molecule Binding Sites Using a Free Energy Model. Journal of Chemical Information and Modeling, 2006, 46, 2631-2637.	2.5	29
111	Computational Sampling of a Cryptic Drug Binding Site in a Protein Receptor: Explicit Solvent Molecular Dynamics and Inhibitor Docking to p38 MAP Kinase. Journal of Molecular Biology, 2006, 359, 202-214.	2.0	91

#	Article	IF	Citations
112	A Src-Like Inactive Conformation in the Abl Tyrosine Kinase Domain. PLoS Biology, 2006, 4, e144.	2.6	277
113	Allosteric p38 kinase inhibitors. Expert Opinion on Therapeutic Patents, 2006, 16, 1443-1448.	2.4	3
114	Signal Transduction Therapy with Rationally Designed Kinase Inhibitors. Current Signal Transduction Therapy, 2006, 1, 67-95.	0.3	43
115	Inhibition of Growth Factor Signaling by Small-Molecule Inhibitors of ErbB, Raf, and MEK. Topics in Medicinal Chemistry, 2006, , 83-132.	0.4	1
116	Mitogen activated protein kinase signaling in the kidney: target for intervention?. Signal Transduction, 2006, 6, 32-53.	0.7	12
117	Computational proteomics of biomolecular interactions in the sequence and structure space of the tyrosine kinome: Deciphering the molecular basis of the kinase inhibitors selectivity. Proteins: Structure, Function and Bioinformatics, 2006, 66, 912-929.	1.5	18
118	Rational design of inhibitors that bind to inactive kinase conformations. Nature Chemical Biology, 2006, 2, 358-364.	3.9	985
119	Mechanisms of drug inhibition of signalling molecules. Nature, 2006, 441, 457-462.	13.7	281
120	Mitogen-activated protein kinases interacting kinases are autoinhibited by a reprogrammed activation segment. EMBO Journal, 2006, 25, 4020-4032.	3.5	71
121	Development of N-2,4-pyrimidine-N-phenyl-Nâ€²-phenyl ureas as inhibitors of tumor necrosis factor alpha (TNF-Î±) synthesis. Part 1. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 3510-3513.	1.0	16
122	Homogeneous time-resolved fluorescence and its applications for kinase assays in drug discovery. Analytical Biochemistry, 2006, 356, 273-281.	1.1	83
123	A General Strategy for Creating â€œInactive-Conformationâ€•Abl Inhibitors. Chemistry and Biology, 2006, 13, 779-786.	6.2	138
124	Catch the Kinase Conformer. Chemistry and Biology, 2006, 13, 693-694.	6.2	8
125	Microwave-assisted synthesis utilizing supported reagents: a rapid and versatile synthesis of 1,5-diarylpyrazoles. Tetrahedron Letters, 2006, 47, 2443-2446.	0.7	42
126	Synthesis ofN-Methoxy-N-methyl-Î²-enaminoketoesters:â€‰ New Synthetic Precursors for the Regioselective Synthesis of Heterocyclic Compounds. Organic Letters, 2006, 8, 3219-3222.	2.4	50
127	Discovery of Novel and Potent Thiazoloquinazolines as Selective Aurora A and B Kinase Inhibitors. Journal of Medicinal Chemistry, 2006, 49, 955-970.	2.9	96
129	Screening for positive allosteric modulators of biological targets. Drug Discovery Today, 2006, 11, 632-639.	3.2	24
131	NMR Characterization of Kinase p38 Dynamics in Free and Ligand-Bound Forms. Angewandte Chemie - International Edition, 2006, 45, 993-997.	7.2	143

#	Article	IF	Citations
132	Small molecular anti-cytokine agents. Medicinal Research Reviews, 2006, 26, 1-62.	5.0	120
134	Structural Biology and Drug Discovery. Current Pharmaceutical Design, 2006, 12, 2087-2097.	0.9	113
135	Readout Technologies for Highly Miniaturized Kinase Assays Applicable to High-Throughput Screening in a 1536-Well Format. Journal of Biomolecular Screening, 2006, 11, 617-633.	2.6	43
136	Novel Targets for Antiinflammatory and Antiarthritic Agents. Current Pharmaceutical Design, 2006, 12, 2437-2454.	0.9	42
137	Discovery and Characterization of Triaminotriazine Aniline Amides as Highly Selective p38 Kinase Inhibitors. Journal of Pharmacology and Experimental Therapeutics, 2006, 318, 495-502.	1.3	16
138	Kinase Drug Discovery by Affinity Selection/Mass Spectrometry (ASMS): Application to DNA Damage Checkpoint Kinase Chk1. Journal of Biomolecular Screening, 2006, 11, 755-764.	2.6	32
139	Incorporating protein flexibility into docking and structure-based drug design. Expert Opinion on Drug Discovery, 2006, 1, 335-349.	2.5	30
140	Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 17783-17788.	3.3	632
141	High-Content Screening Analysis of the p38 Pathway: Profiling of Structurally Related p38Î± Kinase Inhibitors Using Cell-Based Assays. Assay and Drug Development Technologies, 2006, 4, 397-409.	0.6	21
142	Enzyme Fragment Complementation Binding Assay for p38Î± Mitogen-Activated Protein Kinase to Study the Binding Kinetics of Enzyme Inhibitors. Assay and Drug Development Technologies, 2006, 4, 411-420.	0.6	21
143	An efficient rapid system for profiling the cellular activities of molecular libraries. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 3153-3158.	3.3	173
144	The selectivity of protein kinase inhibitors: a further update. Biochemical Journal, 2007, 408, 297-315.	1.7	2,287
145	Sorafenib Functions to Potently Suppress RET Tyrosine Kinase Activity by Direct Enzymatic Inhibition and Promoting RET Lysosomal Degradation Independent of Proteasomal Targeting. Journal of Biological Chemistry, 2007, 282, 29230-29240.	1.6	90
146	p38 MAPK inhibitors in dermatology. Expert Review of Dermatology, 2007, 2, 403-407.	0.3	4
147	In silico three-dimensional pharmacophores for aiding the discovery of the Pfmrk (Plasmodium) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 18 Opinion on Drug Discovery, 2007, 2, 1115-1127.	2.5	1
148	Protein Kinase Inhibitors: Structural Insights Into Selectivity. Current Pharmaceutical Design, 2007, 13, 2751-2765.	0.9	51
149	A Fluorescence Lifetimeâ€“Based Binding Assay to Characterize Kinase Inhibitors. Journal of Biomolecular Screening, 2007, 12, 828-841.	2.6	35
150	Molecular mechanisms involved in the regulation of cytokine production by muramyl dipeptide. Biochemical Journal, 2007, 404, 179-190.	1.7	171

#	Article	IF	Citations
151	Molecular basis of MAPK-activated protein kinase 2:p38 assembly. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 6353-6358.	3.3	104
152	Structural Basis for a High Affinity Inhibitor Bound to Protein Kinase MK2. Journal of Molecular Biology, 2007, 369, 735-745.	2.0	32
153	A Fragment-Based Approach for the Discovery of Isoform-Specific p38Î± Inhibitors. ACS Chemical Biology, 2007, 2, 329-336.	1.6	53
154	Allosteric Modulation of G Proteinâ€“Coupled Receptors. Annual Review of Pharmacology and Toxicology, 2007, 47, 1-51.	4.2	615
155	Inhibitors of Tumor Progression Loci-2 (Tpl2) Kinase and Tumor Necrosis Factor Î± (TNF-Î±) Production:â€‰ Selectivity and in Vivo Antiinflammatory Activity of Novel 8-Substituted-4-anilino-6-aminoquinoline-3-carbonitriles. Journal of Medicinal Chemistry, 2007, 50, 4728-4745.	2.9	50
156	Enzyme Adaptation to Inhibitor Binding:â€‰ A Cryptic Binding Site in Phenylethanolamine N-Methyltransferase. Journal of Medicinal Chemistry, 2007, 50, 4845-4853.	2.9	26
157	Discovery and Optimization of p38 Inhibitors via Computer-Assisted Drug Design. Journal of Medicinal Chemistry, 2007, 50, 4016-4026.	2.9	25
158	Mutagenesis of p38Î± MAP Kinase Establishes Key Roles of Phe169 in Function and Structural Dynamics and Reveals a Novel DFG-OUT State. Biochemistry, 2007, 46, 5687-5696.	1.2	33
159	p38 Pathway Kinases as Anti-inflammatory Drug Targets. Journal of Dental Research, 2007, 86, 800-811.	2.5	211
160	Substrate and Docking Interactions in Serine/Threonine Protein Kinases. Chemical Reviews, 2007, 107, 5065-5081.	23.0	119
161	Dissection of the Recognition Properties of p38 MAP Kinase. Determination of the Binding Mode of a New Pyridinylâ^'Heterocycle Inhibitor Family. Journal of Medicinal Chemistry, 2007, 50, 283-293.	2.9	24
162	Pyrazole carboxamides and carboxylic acids as protein kinase inhibitors in aberrant eukaryotic signal transduction: induction of growth arrest in MCF-7 cancer cells. Organic and Biomolecular Chemistry, 2007, 5, 3963.	1.5	15
163	Nicotinamide adenine dinucleotide metabolism as an attractive target for drug discovery. Expert Opinion on Therapeutic Targets, 2007, 11, 695-705.	1.5	153
164	Tagged Fragment Method for Evolutionary Structure-Based De Novo Lead Generation and Optimization. Journal of Medicinal Chemistry, 2007, 50, 5392-5402.	2.9	35
165	Molecular Recognition of Protein Kinase Binding Pockets for Design of Potent and Selective Kinase Inhibitors. Journal of Medicinal Chemistry, 2007, 50, 409-424.	2.9	474
167	PROGRESS IN ACHIEVING PROOF OF CONCEPT FOR p38 KINASE INHIBITORS. , 2007, , 179-198.		1
168	New Treatments for Psoriasis and Atopic Dermatitis. , 2007, , 969-985.		0
169	Recent Advances in Inflammatory and Immunological Diseases: Focus on Arthritis Therapy. , 2007, , 845-872.		0

#	Article	IF	Citations
170	In silico profiling of tyrosine kinases binding specificity and drug resistance using Monte Carlo simulations with the ensembles of protein kinase crystal structures. Biopolymers, 2007, 85, 333-348.	1.2	25
171	Are MAP Kinases Drug Targets? Yes, but Difficult Ones. ChemMedChem, 2007, 2, 1116-1140.	1.6	40
172	Functional Classification of Protein Kinase Binding Sites Using Cavbase. ChemMedChem, 2007, 2, 1432-1447.	1.6	70
173	Synthesis of 1-aryl-3-(3,4-dihydro-2H-chromen-5-yl) ureas as TNF-Î± inhibitors. Chinese Chemical Letters, 2007, 18, 905-908.	4.8	6
174	New modifications to the area of pyrazole-naphthyl urea based p38 MAP kinase inhibitors that bind to the adenine/ATP site. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 4242-4247.	1.0	16
175	Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia. Acta Crystallographica Section D: Biological Crystallography, 2007, 63, 80-93.	2.5	215
176	Exploitation of structural and regulatory diversity in glutamate racemases. Nature, 2007, 447, 817-822.	13.7	121
177	BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth. British Journal of Haematology, 2007, 136, 414-423.	1.2	49
178	p38 MAP-Kinases pathway regulation, function and role in human diseases. Biochimica Et Biophysica Acta - Molecular Cell Research, 2007, 1773, 1358-1375.	1.9	1,113
179	Insights for the development of specific kinase inhibitors by targeted structural genomics. Drug Discovery Today, 2007, 12, 365-372.	3.2	60
180	A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding. Drug Discovery Today, 2007, 12, 622-633.	3.2	170
181	Potential of p38-MAPK inhibitors in the treatment of ischaemic heart disease. , 2007, 116, 192-206.		84
182	Strategies to design pyrazolyl urea derivatives for p38 kinase inhibition: a molecular modeling study. Journal of Computer-Aided Molecular Design, 2007, 21, 155-166.	1.3	15
183	Understanding hERG inhibition with QSAR models based on a one-dimensional molecular representation. Journal of Computer-Aided Molecular Design, 2007, 21, 379-393.	1.3	17
184	Insights from soft X-rays: the chlorine and sulfur sub-structures of a CK2Î±/DRB complex. Molecular and Cellular Biochemistry, 2008, 316, 15-23.	1.4	14
185	Improving database enrichment through ensemble docking. Journal of Computer-Aided Molecular Design, 2008, 22, 621-627.	1.3	63
186	Visual exploration of structureâ€“activity relationship using maximum common framework. Journal of Computer-Aided Molecular Design, 2008, 22, 571-578.	1.3	8
187	Protein Functional Surfaces: Global Shape Matching and Local Spatial Alignments of Ligand Binding Sites. BMC Structural Biology, 2008, 8, 45.	2.3	63

#	Article	IF	Citations
188	Crystal structure of checkpoint kinase 2 in complex with NSC 109555, a potent and selective inhibitor. Protein Science, 2009, 18, 92-100.	3.1	19
189	High quality binding modes in docking ligands to proteins. Proteins: Structure, Function and Bioinformatics, 2008, 71, 1373-1386.	1.5	39
190	Detailed conformational dynamics of juxtamembrane region and activation loop in câ€Kit kinase activation process. Proteins: Structure, Function and Bioinformatics, 2008, 72, 323-332.	1.5	25
191	Modeling and Selection of Flexible Proteins for Structureâ€Based Drug Design: Backbone and Side Chain Movements in p38 MAPK. ChemMedChem, 2008, 3, 336-344.	1.6	21
192	Towards an Integrated Description of Hydrogen Bonding and Dehydration: Decreasing False Positives in Virtual Screening with the HYDE Scoring Function. ChemMedChem, 2008, 3, 885-897.	1.6	168
193	Dynamics in the p38Î±â€…MAPâ€…Kinaseâ€“SB203580 Complex Observed by Liquidâ€State NMR Spectroscopy. Angewandte Chemie - International Edition, 2008, 47, 3548-3551.	7.2	25
195	N-(3-(Phenylcarbamoyl)arylpyrimidine)-5-carboxamides as potent and selective inhibitors of Lck: Structure, synthesis and SAR. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 1172-1176.	1.0	10
196	Synthesis and SAR of new pyrrolo[2,1-f][1,2,4]triazines as potent p38Î± MAP kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 2739-2744.	1.0	31
197	Structure-based design and subsequent optimization of 2-tolyl-(1,2,3-triazol-1-yl-4-carboxamide) inhibitors of p38 MAP kinase. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 3251-3255.	1.0	22
198	Biphenyl amide p38 kinase inhibitors 3: Improvement of cellular and in vivo activity. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 4428-4432.	1.0	67
199	Kinase array design, back to front: Biaryl amides. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 5285-5289.	1.0	22
200	Staurosporine-based binding assay for testing the affinity of compounds to protein kinases. Analytical Biochemistry, 2008, 373, 197-206.	1.1	13
201	Doing more than just the structureâ€”structural genomics in kinase drug discovery. Current Opinion in Chemical Biology, 2008, 12, 40-45.	2.8	38
202	Small Molecule Recognition of c-Src via the Imatinib-Binding Conformation. Chemistry and Biology, 2008, 15, 1015-1022.	6.2	84
203	Biphenyl amide p38 kinase inhibitors 4: DFG-in and DFG-out binding modes. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 4433-4437.	1.0	58
204	Allosteric regulation and catalysis emerge via a common route. Nature Chemical Biology, 2008, 4, 474-482.	3.9	610
205	High-throughput kinase profiling as a platform for drug discovery. Nature Reviews Drug Discovery, 2008, 7, 391-397.	21.5	198
206	Small-molecule inhibitors binding to protein kinase. Part II: the novel pharmacophore approach of type II and type III inhibition. Expert Opinion on Drug Discovery, 2008, 3, 1427-1449.	2.5	96

#	Article	IF	Citations
207	Type-II Kinase Inhibitor Docking, Screening, and Profiling Using Modified Structures of Active Kinase States. Journal of Medicinal Chemistry, 2008, 51, 7921-7932.	2.9	162
208	Drugging the Plasmodium kinome: the benefits of academiaâ€“industry synergy. Trends in Pharmacological Sciences, 2008, 29, 241-249.	4.0	38
209	Structure-Based Design of Novel 2-Amino-6-phenyl-pyrimido[5â€²,4â€²:5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as Potent and Orally Active Inhibitors of Lymphocyte Specific Kinase (Lck): Synthesis, SAR, and In Vivo Anti-Inflammatory Activity. Journal of Medicinal Chemistry, 2008, 51, 1637-1648.	2.9	59
210	FieldScreen: Virtual Screening Using Molecular Fields. Application to the DUD Data Set. Journal of Chemical Information and Modeling, 2008, 48, 2108-2117.	2.5	115
211	Developing assays for kinase drug discovery â€“ where have the advances come from?. Expert Opinion on Drug Discovery, 2008, 3, 115-129.	2.5	9
212	Kinase inhibitors as drugs for chronic inflammatory and immunological diseases: progress and challenges. Expert Opinion on Therapeutic Targets, 2008, 12, 883-903.	1.5	43
213	Diversity-Oriented Synthesis of Privileged Benzopyranyl Heterocycles from s-cis-Enones. Journal of Organic Chemistry, 2008, 73, 1752-1761.	1.7	75
214	Solution Conformations and Dynamics of ABL Kinase-Inhibitor Complexes Determined by NMR Substantiate the Different Binding Modes of Imatinib/Nilotinib and Dasatinib. Journal of Biological Chemistry, 2008, 283, 18292-18302.	1.6	183
215	Targeting the unactivated conformations of protein kinases for small molecule drug discovery. Expert Opinion on Drug Discovery, 2008, 3, 595-605.	2.5	30
216	The PI3K/Akt Pathway: Recent Progress in the Development of ATP-Competitive and Allosteric Akt Kinase Inhibitors. Current Cancer Drug Targets, 2008, 8, 7-18.	0.8	84
217	Roles for TAB1 in regulating the IL-1-dependent phosphorylation of the TAB3 regulatory subunit and activity of the TAK1 complex. Biochemical Journal, 2008, 409, 711-722.	1.7	59
218	Alternative p38 MAPK Pathways. , 2007, , 17-32.		2
219	Structural biology in the battle against BCR-Abl. Expert Opinion on Therapeutic Patents, 2008, 18, 975-988.	2.4	0
220	Reassessing a sparse energetic network within a single protein domain. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 4679-4684.	3.3	89
221	Non-ATP-competitive kinase inhibitors â€“ enhancing selectivity through new inhibition strategies. Expert Opinion on Drug Discovery, 2008, 3, 761-774.	2.5	14
222	Seven Transmembrane Receptors as Nature's Prototype Allosteric Protein: De-emphasizing the Geography of Binding. Molecular Pharmacology, 2008, 74, 541-543.	1.0	17
223	Alternative assay formats to identify diverse inhibitors of protein kinases. Expert Opinion on Drug Discovery, 2008, 3, 819-831.	2.5	4
224	Protein Kinase Inhibitors Highlight the Complexities of Drug-Target Non-Covalent Interactions. Biotechnology and Biotechnological Equipment, 2008, 22, 772-777.	0.5	0

#	Article	IF	Citations
225	Targeting inactive kinases: structure as a foundation for cancer drug discovery. , 2008, , 229-252.		7
228	Nuclear Localization of p38 MAPK in Response to DNA Damage. International Journal of Biological Sciences, 2009, 5, 428-437.	2.6	119
229	The Therapeutic Potential of LRRK2 and Î±-Synuclein in Parkinson's Disease. Antioxidants and Redox Signaling, 2009, 11, 2167-2187.	2.5	9
230	Structural Characterization of Proline-rich Tyrosine Kinase 2 (PYK2) Reveals a Unique (DFG-out) Conformation and Enables Inhibitor Design. Journal of Biological Chemistry, 2009, 284, 13193-13201.	1.6	90
231	Development of Extracellular Signal-Regulated Kinase Inhibitors. Current Topics in Medicinal Chemistry, 2009, 9, 678-689.	1.0	30
232	Development and Applications of a Broad-Coverage, TR-FRET-Based Kinase Binding Assay Platform. Journal of Biomolecular Screening, 2009, 14, 924-935.	2.6	74
233	Molecular Dynamics as a Tool in Rational Drug Design: Current Status and Some Major Applications. Current Computer-Aided Drug Design, 2009, 5, 225-240.	0.8	38
234	Inhibition of basal p38 or JNK activity enhances epithelial barrier function through differential modulation of claudin expression. American Journal of Physiology - Cell Physiology, 2009, 297, C775-C787.	2.1	64
235	Role of protein haptenation in triggering maturation events in the dendritic cell surrogate cell line THP-1. Toxicology and Applied Pharmacology, 2009, 238, 120-132.	1.3	39
236	Inhibition of pro-inflammatory cytokine production by the dual p38/JNK2 inhibitor BIRB796 correlates with the inhibition of p38 signaling. Biochemical Pharmacology, 2009, 77, 422-432.	2.0	28
237	The structural basis of allosteric regulation in proteins. FEBS Letters, 2009, 583, 1692-1698.	1.3	187
238	Signaling events leading to peroxiredoxin 5 up-regulation in immunostimulated macrophages. Free Radical Biology and Medicine, 2009, 47, 794-802.	1.3	41
239	The interplay of structural information and functional studies in kinase drug design: insights from BCR-Abl. Current Opinion in Cell Biology, 2009, 21, 288-295.	2.6	54
240	New and emerging biologics in the treatment of inflammatory bowel disease: quo vadis?. Gastroenterologie Clinique Et Biologique, 2009, 33, S217-S227.	0.9	14
241	MALDIâ€TOF Massâ€Spectrometryâ€Based Versatile Method for the Characterization of Protein Kinases. Chemistry - A European Journal, 2009, 15, 1413-1421.	1.7	18
242	Engineering Allosteric Regulation into Biological Catalysts. ChemBioChem, 2009, 10, 2824-2835.	1.3	40
243	Advances in the development of kinase inhibitor therapeutics for Alzheimer's disease. Drug Development Research, 2009, 70, 125-144.	1.4	33
244	Fragment-based lead generation: identification of seed fragments by a highly efficient fragment screening technology. Journal of Computer-Aided Molecular Design, 2009, 23, 501-511.	1.3	18

#	Article	IF	Citations
245	Protein and lipid kinase inhibitors as targeted anticancer agents of the Ras/Raf/MEK and PI3K/PKB pathways. Purinergic Signalling, 2009, 5, 117-125.	1.1	25
246	Protein Kinase CK2 in Health and Disease. Cellular and Molecular Life Sciences, 2009, 66, 1800-1816.	2.4	90
247	Cell cycle kinases predicted from conserved biophysical properties. Proteins: Structure, Function and Bioinformatics, 2009, 74, 655-668.	1.5	2
248	Application of the PM6 semi-empirical method to modeling proteins enhances docking accuracy of AutoDock. Journal of Cheminformatics, 2009, 1, 15.	2.8	445
249	The Design, Synthesis and Potential Utility of Fluorescence Probes that Target DFGâ€out Conformation of p38Î± for High Throughput Screening Binding Assay. Chemical Biology and Drug Design, 2009, 74, 547-559.	1.5	10
250	New Protein Kinase CK2 Inhibitors: Jumping out of the Catalytic Box. Chemistry and Biology, 2009, 16, 112-120.	6.2	95
251	Identification of amidoheteroaryls as potent inhibitors of mutant (V600E) B-Raf kinase with in vivo activity. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 1026-1029.	1.0	9
252	Discovery and characterization of the N-phenyl-Nâ€²-naphthylurea class of p38 kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 2386-2391.	1.0	6
253	The Chemical Biology of Protein Phosphorylation. Annual Review of Biochemistry, 2009, 78, 797-825.	5.0	213
254	LigMatch: A Multiple Structure-Based Ligand Matching Method for 3D Virtual Screening. Journal of Chemical Information and Modeling, 2009, 49, 2056-2066.	2.5	35
255	9-(Arenethenyl)purines as Dual Src/Abl Kinase Inhibitors Targeting the Inactive Conformation: Design, Synthesis, and Biological Evaluation. Journal of Medicinal Chemistry, 2009, 52, 4743-4756.	2.9	41
256	Protein kinase inhibitors: contributions from structure to clinical compounds. Quarterly Reviews of Biophysics, 2009, 42, 1-40.	2.4	228
257	SHOP: Receptor-Based Scaffold HOPping by GRID-Based Similarity Searches. Journal of Chemical Information and Modeling, 2009, 49, 658-669.	2.5	19
258	Fragment-Based Computation of Binding Free Energies by Systematic Sampling. Journal of Chemical Information and Modeling, 2009, 49, 1901-1913.	2.5	36
259	Characterization of the CHK1 Allosteric Inhibitor Binding Site. Biochemistry, 2009, 48, 9823-9830.	1.2	41
260	QM/MM Calculations in Drug Discovery: A Useful Method for Studying Binding Phenomena?. Journal of Chemical Information and Modeling, 2009, 49, 670-677.	2.5	74
261	An Evaluation of Explicit Receptor Flexibility in Molecular Docking Using Molecular Dynamics and Torsion Angle Molecular Dynamics. Journal of Chemical Theory and Computation, 2009, 5, 2909-2923.	2.3	48
262	Characterization of a murine keyhole limpet hemocyanin (KLH)-delayed-type hypersensitivity (DTH) model: Role for p38 kinase. International Immunopharmacology, 2009, 9, 1218-1227.	1.7	10

#	Article	IF	Citations
263	First Inactive Conformation of CK2Î±, the Catalytic Subunit of Protein Kinase CK2. Journal of Molecular Biology, 2009, 386, 1212-1221.	2.0	30
264	Binding Site Similarity Analysis for the Functional Classification of the Protein Kinase Family. Journal of Chemical Information and Modeling, 2009, 49, 318-329.	2.5	82
265	Selective Inhibitors of the Mutant B-Raf Pathway: Discovery of a Potent and Orally Bioavailable Aminoisoquinoline. Journal of Medicinal Chemistry, 2009, 52, 6189-6192.	2.9	92
266	The regulation of protein phosphorylation. Biochemical Society Transactions, 2009, 37, 627-641.	1.6	245
267	The p38 MAPK inhibitors for the treatment of inflammatory diseases and cancer. Expert Opinion on Investigational Drugs, 2009, 18, 1893-1905.	1.9	279
268	Structural Bioinformatics-Based Prediction of Exceptional Selectivity of p38 MAP Kinase Inhibitor PH-797804. Biochemistry, 2009, 48, 6402-6411.	1.2	55
269	Steered Molecular Dynamics Simulations Reveal the Likelier Dissociation Pathway of Imatinib from Its Targeting Kinases c-Kit and Abl. PLoS ONE, 2009, 4, e8470.	1.1	41
270	High-Throughput Screening To Identify Inhibitors Which Stabilize Inactive Kinase Conformations in p38Î±. Journal of the American Chemical Society, 2009, 131, 18478-18488.	6.6	80
271	Binding Site Detection and Druggability Index from First Principles. Journal of Medicinal Chemistry, 2009, 52, 2363-2371.	2.9	201
273	Fragment-Based Drug Discovery of Kinase Inhibitors. , 0, , 461-483.		16
274	Practical Use of Computational Chemistry in Kinase Drug Discovery. , 0, , 403-431.		0
275	Development of a Fluorescent-Tagged Kinase Assay System for the Detection and Characterization of Allosteric Kinase Inhibitors. Journal of the American Chemical Society, 2009, 131, 13286-13296.	6.6	140
276	Molecular Basis of Inactive B-RAFWT and B-RAFV600E Ligand Inhibition, Selectivity and Conformational Stability: An in Silico Study. Molecular Pharmaceutics, 2009, 6, 144-157.	2.3	15
277	Affinity Classification of Kinase Inhibitors by Mass Spectrometric Methods and Validation Using Standard IC50 Measurements. Analytical Chemistry, 2009, 81, 408-419.	3.2	27
278	Allosteric Drug Antagonism. , 2009, , 129-147.		1
279	Hybrid Compound Design To Overcome the Gatekeeper T338M Mutation in cSrc. Journal of Medicinal Chemistry, 2009, 52, 3915-3926.	2.9	128
280	Novel Potent BRAF Inhibitors: Toward 1 nM Compounds through Optimization of the Central Phenyl Ring. Journal of Medicinal Chemistry, 2009, 52, 3881-3891.	2.9	46
281	Anti-Inflammatory Properties of a NovelN-Phenyl Pyridinone Inhibitor of p38 Mitogen-Activated Protein Kinase: Preclinical-to-Clinical Translation. Journal of Pharmacology and Experimental Therapeutics, 2009, 331, 882-895.	1.3	57

#	Article	IF	Citations
282	A new screening assay for allosteric inhibitors of cSrc. Nature Chemical Biology, 2009, 5, 394-396.	3.9	114
283	Technique for Energy Decomposition in the Study of â€œReceptor-Ligandâ€•Complexes. Journal of Chemical Information and Modeling, 2009, 49, 1389-1406.	2.5	47
284	Inhibition of the Insulin-like Growth Factor-1 Receptor (IGF1R) Tyrosine Kinase as a Novel Cancer Therapy Approach. Journal of Medicinal Chemistry, 2009, 52, 4981-5004.	2.9	119
285	Rapid synthesis of Abelson tyrosine kinase inhibitors using click chemistry. Organic and Biomolecular Chemistry, 2009, 7, 5129.	1.5	38
288	Disruption of angiogenesis and tumor growth with an orally active drug that stabilizes the inactive state of PDGFRÎ²/B-RAF. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 4299-4304.	3.3	55
289	Selectively Nonselective Kinase Inhibition: Striking the Right Balance. Journal of Medicinal Chemistry, 2010, 53, 1413-1437.	2.9	280
290	Novel Synthesis and Structural Characterization of a High-Affinity Paramagnetic Kinase Probe for the Identification of Non-ATP Site Binders by Nuclear Magnetic Resonance. Journal of Medicinal Chemistry, 2010, 53, 1238-1249.	2.9	24
291	Development of an online p38Î± mitogen-activated protein kinase binding assay and integration of LCâ€“HR-MS. Analytical and Bioanalytical Chemistry, 2010, 398, 1771-1780.	1.9	32
292	The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors: A structural analysis of the binding interactions of GleevecÂ®, NexavarÂ®, and BIRB-796. Bioorganic and Medicinal Chemistry, 2010, 18, 5738-5748.	1.4	143
293	Mitogen-activated protein kinase pathway inhibitors: inhibitors for diseases?. Frontiers of Medicine in China, 2010, 4, 46-53.	0.1	1
294	Two additive mechanisms impair the differentiation of 'substrate-selective' p38 inhibitors from classical p38 inhibitors in vitro. BMC Systems Biology, 2010, 4, 23.	3.0	9
295	KR-003048, a potent, orally active inhibitor of p38 mitogen-activated protein kinase. European Journal of Pharmacology, 2010, 632, 93-102.	1.7	10
296	A structural informatics approach to mine kinase knowledge bases. Drug Discovery Today, 2010, 15, 203-209.	3.2	7
297	Study of the in vivo phosphorylation of E2F1 on Ser403. Biochimica Et Biophysica Acta - Molecular Cell Research, 2010, 1803, 912-918.	1.9	12
298	Caspase-8-mediated cleavage of Bid and protein phosphatase 2A-mediated activation of Bax are necessary for Verotoxin-1-induced apoptosis in Burkitt's lymphoma cells. Cellular Signalling, 2010, 22, 467-475.	1.7	20
299	Inhibitors of p38 suppress cytokine production in rheumatoid arthritis synovial membranes: Does variable inhibition of interleukinâ€6 production limit effectiveness in vivo?. Arthritis and Rheumatism, 2010, 62, 3221-3231.	6.7	35
300	Conformational plasticity of the catalytic subunit of protein kinase CK2 and its consequences for regulation and drug design. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2010, 1804, 484-492.	1.1	42
301	A convenient and efficient protocol for the synthesis of 5-aryl-1,3-diphenylpyrazole catalyzed by hydrochloric acid under ultrasound irradiation. Ultrasonics Sonochemistry, 2010, 17, 11-13.	3.8	53

#	Article	IF	Citations
302	Fluorescence polarization binding assay to develop inhibitors of inactive p38Î± mitogen-activated protein kinase. Analytical Biochemistry, 2010, 401, 125-133.	1.1	19
303	Affinity Reagents that Target a Specific Inactive Form of Protein Kinases. Chemistry and Biology, 2010, 17, 195-206.	6.2	36
304	Activation State-Dependent Binding of Small Molecule Kinase Inhibitors: Structural Insights from Biochemistry. Chemistry and Biology, 2010, 17, 1241-1249.	6.2	90
305	Application of a novel [3+2] cycloaddition reaction to prepare substituted imidazoles and their use in the design of potent DFG-out allosteric B-Raf inhibitors. Bioorganic and Medicinal Chemistry, 2010, 18, 292-304.	1.4	47
306	Structure-based drug design enables conversion of a DFG-in binding CSF-1R kinase inhibitor to a DFG-out binding mode. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 1543-1547.	1.0	32
307	Biochemical and biophysical characterization of unique switch pocket inhibitors of p38Î±. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 5787-5792.	1.0	12
308	Enhanced selectivity profile of pyrazole-urea based DFG-out p38Î± inhibitors. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 4885-4891.	1.0	9
309	X-ray crystal structure of JNK2 complexed with the p38Î± inhibitor BIRB796: Insights into the rational design of DFG-out binding MAP kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 5217-5220.	1.0	30
310	Switch control pocket inhibitors of p38-MAP kinase. Durable type II inhibitors that do not require binding into the canonical ATP hinge region. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 5793-5798.	1.0	26
311	Structural analysis of an MK2â€“inhibitor complex: insight into the regulation of the secondary structure of the Gly-rich loop by TEI-I01800. Acta Crystallographica Section D: Biological Crystallography, 2010, 66, 80-87.	2.5	9
312	An inhibited conformation for the protein kinase domain of theSaccharomyces cerevisiaeAMPK homolog Snf1. Acta Crystallographica Section F: Structural Biology Communications, 2010, 66, 999-1002.	0.7	7
313	A Protein Relational Database and Protein Family Knowledge Bases to Facilitate Structureâ€Based Design Analyses. Chemical Biology and Drug Design, 2010, 76, 142-153.	1.5	7
315	Structural Mechanisms of Slow-Onset, Two-Step Enzyme Inhibition. Current Chemical Biology, 2010, 4, 64-73.	0.2	1
316	Use of p38 MAPK Inhibitors for the Treatment of Werner Syndrome. Pharmaceuticals, 2010, 3, 1842-1872.	1.7	29
317	Crystal Structure of Human AKT1 with an Allosteric Inhibitor Reveals a New Mode of Kinase Inhibition. PLoS ONE, 2010, 5, e12913.	1.1	247
318	Structure-based drug design case study: p38. , 0, , 197-208.		0
319	p38 maintains E-cadherin expression by modulating TAK1â€“NF-ÎºB during epithelial-to-mesenchymal transition. Journal of Cell Science, 2010, 123, 4321-4331.	1.2	84
320	Crystal structure of an Aurora-A mutant that mimics Aurora-B bound to MLN8054: insights into selectivity and drug design. Biochemical Journal, 2010, 427, 19-28.	1.7	86

#	Article	IF	Citations
321	Biological therapies of inflammatory bowel disease. Immunotherapy, 2010, 2, 727-742.	1.0	10
322	Ligand Detection in the Allosteric World. Journal of Biomolecular Screening, 2010, 15, 119-130.	2.6	54
323	Activation of the Nucleotide Oligomerization Domain Signaling Pathway by the Non-bacterially Derived Xanthone Drug 5â€²6-Dimethylxanthenone-4-acetic Acid (Vadimezan)*. Journal of Biological Chemistry, 2010, 285, 10553-10562.	1.6	17
324	Kinase selectivity potential for inhibitors targeting the ATP binding site: a network analysis. Bioinformatics, 2010, 26, 198-204.	1.8	127
325	Mechanisms of Allostery and Membrane Attachment in Ras GTPases: Implications for Anti-Cancer Drug Discovery. Current Medicinal Chemistry, 2010, 17, 1-9.	1.2	51
326	Structural Mechanisms of Slow-Onset, Two-Step Enzyme Inhibition. Current Chemical Biology, 2010, 4, 64-73.	0.2	13
327	Comprehensive Comparison of Ligand-Based Virtual Screening Tools Against the DUD Data set Reveals Limitations of Current 3D Methods. Journal of Chemical Information and Modeling, 2010, 50, 2079-2093.	2.5	121
328	Selective p38Î± Inhibitors Clinically Evaluated for the Treatment of Chronic Inflammatory Disorders. Journal of Medicinal Chemistry, 2010, 53, 2345-2353.	2.9	166
329	Displacement Assay for the Detection of Stabilizers of Inactive Kinase Conformations. Journal of Medicinal Chemistry, 2010, 53, 357-367.	2.9	26
330	Through the â€œGatekeeper Doorâ€ Exploiting the Active Kinase Conformation. Journal of Medicinal Chemistry, 2010, 53, 2681-2694.	2.9	432
331	Developing small molecules to inhibit kinases unkind to the heart: p38 MAPK as a case in point. Drug Discovery Today Disease Mechanisms, 2010, 7, e123-e127.	0.8	26
332	Fluorophore Labeling of the Glycine-Rich Loop as a Method of Identifying Inhibitors That Bind to Active and Inactive Kinase Conformations. Journal of the American Chemical Society, 2010, 132, 4152-4160.	6.6	50
333	Seven Transmembrane Receptors as Shapeshifting Proteins: The Impact of Allosteric Modulation and Functional Selectivity on New Drug Discovery. Pharmacological Reviews, 2010, 62, 265-304.	7.1	543
334	Targeting p38 MAPK pathway for the treatment of Alzheimer's disease. Neuropharmacology, 2010, 58, 561-568.	2.0	309
335	Feeling the stress: MAPKKK-MAPKK-MAPK signaling cascades in heart failure. Journal of Molecular and Cellular Cardiology, 2010, 48, 283-285.	0.9	3
336	Mechanisms and functions of p38 MAPK signalling. Biochemical Journal, 2010, 429, 403-417.	1.7	1,342
337	Analysis of Imatinib and Sorafenib Binding to p38Î± Compared with c-Abl and b-Raf Provides Structural Insights for Understanding the Selectivity of Inhibitors Targeting the DFG-Out Form of Protein Kinases. Biochemistry, 2010, 49, 3611-3618.	1.2	63
339	One-Pot Synthesis of 4,6-Diaryl-2-oxo(imino)-1,2-dihydropyridine-3-carbonitrile; a New Scaffold for p38Î± MAP Kinase Inhibition. ACS Combinatorial Science, 2010, 12, 559-565.	3.3	19

#	Article	IF	Citations
340	Leucine-Rich Repeat Kinase 2 (LRRK2) Cellular Biology: A Review of Recent Advances in Identifying Physiological Substrates and Cellular Functions. Journal of Neurogenetics, 2011, 25, 140-151.	0.6	40
341	Transplantâ^'Insertâ^'Constrainâ^'Relaxâ^'Assemble (TICRA): Proteinâ^'Ligand Complex Structure Modeling and Application to Kinases. Journal of Chemical Information and Modeling, 2011, 51, 52-60.	2.5	1
342	Understanding the Origins of Time-Dependent Inhibition by Polypeptide Deformylase Inhibitors. Biochemistry, 2011, 50, 6642-6654.	1.2	5
343	Importance of Domain Closure for the Autoactivation of ERK2. Biochemistry, 2011, 50, 8038-8048.	1.2	29
344	Sequence, Structure, and Active Site Analyses of p38 MAP Kinase: Exploiting DFG-out Conformation as a Strategy to Design New Type II Leads. Journal of Chemical Information and Modeling, 2011, 51, 115-129.	2.5	39
345	Biochemical Characterization of TAK-593, a Novel VEGFR/PDGFR Inhibitor with a Two-Step Slow Binding Mechanism. Biochemistry, 2011, 50, 738-751.	1.2	35
346	A p38Î±-Selective Chemosensor for use in Unfractionated Cell Lysates. ACS Chemical Biology, 2011, 6, 101-105.	1.6	32
347	Using Consensus-Shape Clustering To Identify Promiscuous Ligands and Protein Targets and To Choose the Right Query for Shape-Based Virtual Screening. Journal of Chemical Information and Modeling, 2011, 51, 1233-1248.	2.5	39
348	Discovery of a Potential Allosteric Ligand Binding Site in CDK2. ACS Chemical Biology, 2011, 6, 492-501.	1.6	151
349	Reaction-driven de novo design, synthesis and testing of potential type II kinase inhibitors. Future Medicinal Chemistry, 2011, 3, 415-424.	1.1	37
350	Chapter 4. The Mechanisms and Kinetics of Protein Kinase Inhibitors. RSC Drug Discovery Series, 2011, , 96-125.	0.2	0
352	Transformation ofin vitrotools for kinase profiling: keeping an eye over the off-target liabilities. Expert Opinion on Drug Discovery, 2011, 6, 701-712.	2.5	7
353	Shielded Hydrogen Bonds as Structural Determinants of Binding Kinetics: Application in Drug Design. Journal of the American Chemical Society, 2011, 133, 18903-18910.	6.6	178
354	HTS Reporter Displacement Assay for Fragment Screening and Fragment Evolution Toward Leads with Optimized Binding Kinetics, Binding Selectivity, and Thermodynamic Signature. Methods in Enzymology, 2011, 493, 299-320.	0.4	45
355	Conformational adaptation in drugâ€"target interactions and residence time. Future Medicinal Chemistry, 2011, 3, 1491-1501.	1.1	177
356	Pharmacophore Design of p38α MAP Kinase Inhibitors with Either 2,4,5-Trisubstituted or 1,2,4,5-Tetrasubstituted Imidazole Scaffold. Current Medicinal Chemistry, 2011, 18, 1526-1539.	1.2	22
357	Molecular Interaction Studies Using Microscale Thermophoresis. Assay and Drug Development Technologies, 2011, 9, 342-353.	0.6	655
358	The p38 mitogen-activated protein kinase pathwayâ€"A potential target for intervention in infarction, hypertrophy, and heart failure. Journal of Molecular and Cellular Cardiology, 2011, 51, 485-490.	0.9	134

#	Article	IF	Citations
359	Discovery of pyrrolo[2,1-f][1,2,4]triazine C6-ketones as potent, orally active p38Î± MAP kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 4633-4637.	1.0	13
362	The Importance of Being Profiled: Improving Drug Candidate Safety and Efficacy Using Ion Channel Profiling. Frontiers in Pharmacology, 2011, 2, 78.	1.6	21
363	The Energy Landscape Analysis of Cancer Mutations in Protein Kinases. PLoS ONE, 2011, 6, e26071.	1.1	39
364	Activation of p38 MAPK in CD4 T cells controls IL-17 production and autoimmune encephalomyelitis. Blood, 2011, 118, 3290-3300.	0.6	141
365	The role of a Brugia malayi p38 MAP kinase ortholog (Bm-MPK1) in parasite anti-oxidative stress responses. Molecular and Biochemical Parasitology, 2011, 176, 90-97.	0.5	31
366	Biochemical characterization of a novel type-II VEGFR2 kinase inhibitor: Comparison of binding to non-phosphorylated and phosphorylated VEGFR2. Bioorganic and Medicinal Chemistry, 2011, 19, 5342-5351.	1.4	21
367	Discovery of indazoles as inhibitors of Tpl2 kinase. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 4758-4761.	1.0	17
368	Discovery of a novel class of non-ATP site DFG-out state p38 inhibitors utilizing computationally assisted virtual fragment-based drug design (vFBDD). Bioorganic and Medicinal Chemistry Letters, 2011, 21, 7155-7165.	1.0	26
369	Structure-based design of isoindoline-1,3-diones and 2,3-dihydrophthalazine-1,4-diones as novel B-Raf inhibitors. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 6941-6944.	1.0	11
370	Contemporary Approaches to Kinase Lead Generation. RSC Drug Discovery Series, 2011, , 54-78.	0.2	0
371	Molecular mechanisms of drug resistance in tyrosine kinases cAbl and cKit. Critical Reviews in Biochemistry and Molecular Biology, 2011, 46, 295-309.	2.3	13
372	Selectivity of Kinase Inhibitor Fragments. Journal of Medicinal Chemistry, 2011, 54, 5131-5143.	2.9	65
373	Molecular Dynamics Simulation and Free Energy Calculation Studies of the Binding Mechanism of Allosteric Inhibitors with p38Î± MAP Kinase. Journal of Chemical Information and Modeling, 2011, 51, 3235-3246.	2.5	67
374	Discovery and Characterization of Non-ATP Site Inhibitors of the Mitogen Activated Protein (MAP) Kinases. ACS Chemical Biology, 2011, 6, 234-244.	1.6	77
375	Application of shape-based and pharmacophore-based in silico screens for identification of Type II protein kinase inhibitors. Journal of Computer-Aided Molecular Design, 2011, 25, 569-581.	1.3	9
376	Network approach for capturing ligand-induced subtle global changes in protein structures. Acta Crystallographica Section D: Biological Crystallography, 2011, 67, 429-439.	2.5	18
377	Structural basis for compound C inhibition of the human AMP-activated protein kinase Î±2 subunit kinase domain. Acta Crystallographica Section D: Biological Crystallography, 2011, 67, 480-487.	2.5	64
378	A theoretical entropy score as a single value to express inhibitor selectivity. BMC Bioinformatics, 2011, 12, 94.	1.2	36

#	Article	IF	Citations
379	Analysis of water patterns in protein kinase binding sites. Proteins: Structure, Function and Bioinformatics, 2011, 79, 2109-2121.	1.5	22
380	Using Spherical Harmonic Surface Property Representations for Ligandâ€Based Virtual Screening. Molecular Informatics, 2011, 30, 151-159.	1.4	10
381	Design, Synthesis, and Biological Activity of Urea Derivatives as Anaplastic Lymphoma Kinase Inhibitors. ChemMedChem, 2011, 6, 1680-1692.	1.6	18
382	Role of protein flexibility in the discovery of new drugs. Drug Development Research, 2011, 72, 26-35.	1.4	14
383	Fragment and protein simulation methods in fragment based drug design. Drug Development Research, 2011, 72, 130-137.	1.4	2
384	In Situ Kinase Profiling Reveals Functionally Relevant Properties of Native Kinases. Chemistry and Biology, 2011, 18, 699-710.	6.2	292
385	Potent and selective thiophene urea-templated inhibitors of S6K. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 849-852.	1.0	14
386	Protein Flexibility and Ligand Recognition: Challenges for Molecular Modeling. Current Topics in Medicinal Chemistry, 2011, 11, 192-210.	1.0	86
387	The Dark Side of Protein Kinase CK2 Inhibition. Current Medicinal Chemistry, 2011, 18, 2867-2884.	1.2	37
389	Inhibition of SAPK2/p38 Enhances Sensitivity to mTORC1 Inhibition by Blocking IRES-Mediated Translation Initiation in Glioblastoma. Molecular Cancer Therapeutics, 2011, 10, 2244-2256.	1.9	20
390	Multidimensional Profiling of CSF1R Screening Hits and Inhibitors. Journal of Biomolecular Screening, 2011, 16, 1007-1017.	2.6	18
392	Genetic and Pharmacological Inhibition of PDK1 in Cancer Cells. Journal of Biological Chemistry, 2011, 286, 6433-6448.	1.6	56
393	Tinkering outside the kinase ATP box: allosteric (type IV) and bivalent (type V) inhibitors of protein kinases. Future Medicinal Chemistry, 2011, 3, 29-43.	1.1	50
398	Trapping Conformational States Along Ligand-Binding Dynamics of Peptide Deformylase: The Impact of Induced Fit on Enzyme Catalysis. PLoS Biology, 2011, 9, e1001066.	2.6	30
399	Biosensor-Based Approach to the Identification of Protein Kinase Ligands with Dual-Site Modes of Action. Journal of Biomolecular Screening, 2012, 17, 183-193.	2.6	23
400	Structural Basis for the Regulation of Protein Kinase A by Activation Loop Phosphorylation. Journal of Biological Chemistry, 2012, 287, 14672-14680.	1.6	76
401	New Therapeutic Targets in Cardiology. Circulation, 2012, 126, 357-368.	1.6	68
402	The Different Ways through Which Specificity Works in Orthosteric and Allosteric Drugs. Current Drug Metabolism, 2012, 18, 1311-1316.	0.7	5

#	Article	IF	Citations
403	Identifying and characterizing promiscuous targets: Implications for virtual screening. Expert Opinion on Drug Discovery, 2012, 7, 1-17.	2.5	14
404	Computational Design of Targeted Inhibitors of Polo-Like Kinase 1 (Plk1). Bioinformatics and Biology Insights, 2012, 6, BBI.S8971.	1.0	8
405	Exploiting Substrate Recognition for Selective Inhibition of Protein Kinases. Current Pharmaceutical Design, 2012, 18, 2914-2920.	0.9	10
406	Computational Insights for the Discovery of Non-ATP Competitive Inhibitors of MAP Kinases. Current Pharmaceutical Design, 2012, 18, 1173-1185.	0.9	19
407	The Different Ways through Which Specificity Works in Orthosteric and Allosteric Drugs. Current Pharmaceutical Design, 2012, 18, 1311-1316.	0.9	98
408	A Back-to-Front Fragment-Based Drug Design Search Strategy Targeting the DFG-Out Pocket of Protein Tyrosine Kinases. ACS Medicinal Chemistry Letters, 2012, 3, 342-346.	1.3	25
409	Affinity-Based Probes Based on Type II Kinase Inhibitors. Journal of the American Chemical Society, 2012, 134, 19017-19025.	6.6	47
410	TSLP Signaling Network Revealed by SILAC-Based Phosphoproteomics. Molecular and Cellular Proteomics, 2012, 11, M112.017764.	2.5	47
411	Discovery of GNF-5837, a Selective TRK Inhibitor with Efficacy in Rodent Cancer Tumor Models. ACS Medicinal Chemistry Letters, 2012, 3, 140-145.	1.3	82
412	Docking, synthesis and pharmacological activity of novel urea-derivatives designed as p38 MAPK inhibitors. European Journal of Medicinal Chemistry, 2012, 54, 264-271.	2.6	14
413	Consensus Induced Fit Docking (cIFD): methodology, validation, and application to the discovery of novel Crm1 inhibitors. Journal of Computer-Aided Molecular Design, 2012, 26, 1217-1228.	1.3	62
414	Investigation of the effect of molecular properties on the binding kinetics of a ligand to its biological target. MedChemComm, 2012, 3, 449.	3.5	50
415	Molecular dynamics and free energy studies on Aurora kinase A and its mutant bound with MLN8054: insight into molecular mechanism of subtype selectivity. Molecular BioSystems, 2012, 8, 3049.	2.9	24
416	A flow cytometry-based dopamine transporter binding assay using antagonist-conjugated quantum dots. Chemical Communications, 2012, 48, 5428.	2.2	13
417	Druggability Assessment of Allosteric Proteins by Dynamics Simulations in the Presence of Probe Molecules. Journal of Chemical Theory and Computation, 2012, 8, 2435-2447.	2.3	138
418	Design and synthesis of novel p38Î± MAP kinase inhibitors: Discovery of pyrazole-benzyl ureas bearing 2-molpholinopyrimidine moiety. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 5118-5122.	1.0	14
419	Identifying Allosteric Binding Sites in Proteins with a Two-State Goì... Model for Novel Allosteric Effector Discovery. Journal of Chemical Theory and Computation, 2012, 8, 2962-2971.	2.3	46
420	Dual Inhibition of Phosphodiesterase-4 and p38 MAP Kinase: A Strategy for Treatment of Chronic Inflammatory Diseases. RSC Drug Discovery Series, 2012, , 137-157.	0.2	1

#	Article	IF	Citations
421	2-Benzamido-N-(1H-benzo[d]imidazol-2-yl)thiazole-4-carboxamide derivatives as potent inhibitors of CK1Î´/Îµ. Amino Acids, 2012, 43, 1577-1591.	1.2	41
422	The Crystal Structure of the MAP Kinase LmaMPK10 from Leishmania Major Reveals Parasite-Specific Features and Regulatory Mechanisms. Structure, 2012, 20, 1649-1660.	1.6	19
423	Development and strategies of VEGFR-2/KDR inhibitors. Future Medicinal Chemistry, 2012, 4, 1839-1852.	1.1	63
424	Determination of the Kinetics and Thermodynamics of Ligand Binding to a Specific Inactive Conformation in Protein Kinases. Methods in Molecular Biology, 2012, 928, 153-159.	0.4	2
425	Targeting GSK3 from Ustilago maydis: Type-II Kinase Inhibitors as Potential Antifungals. ACS Chemical Biology, 2012, 7, 1257-1267.	1.6	18
426	Rational Drug Design. Methods in Molecular Biology, 2012, , .	0.4	2
428	Novel Binding Mode of a Potent and Selective Tankyrase Inhibitor. PLoS ONE, 2012, 7, e33740.	1.1	55
429	Discovery of Novel Orally Active Anti-Inflammatory N-Phenylpyrazolyl-N-Glycinyl-Hydrazone Derivatives That Inhibit TNF-Î± Production. PLoS ONE, 2012, 7, e46925.	1.1	21
430	Rational Approaches to Improving Selectivity in Drug Design. Journal of Medicinal Chemistry, 2012, 55, 1424-1444.	2.9	248
431	p38 Inhibitor SB203580 sensitizes the resveratrolâ€induced apoptosis in human lung adenocarcinoma (A549) cells. Journal of Biochemical and Molecular Toxicology, 2012, 26, 251-257.	1.4	5
432	Virtual screening using a conformationally flexible target protein: models for ligand binding to p38Î± MAPK. Journal of Computer-Aided Molecular Design, 2012, 26, 409-423.	1.3	15
434	A Novel Mechanism by Which Small Molecule Inhibitors Induce the DFG Flip in Aurora A. ACS Chemical Biology, 2012, 7, 698-706.	1.6	58
435	Can biochemistry drive drug discovery beyond simple potency measurements?. Drug Discovery Today, 2012, 17, 388-395.	3.2	5
436	Structure-based design, synthesis and biological evaluation of N-pyrazole, Nâ€²-thiazole urea inhibitors of MAP kinase p38Î±. European Journal of Medicinal Chemistry, 2012, 48, 1-15.	2.6	29
437	Design and synthesis of 4-alkynyl pyrazoles as inhibitors of PDE4: A practical access via Pd/Câ€“Cu catalysis. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 2480-2487.	1.0	16
438	The discovery of N-cyclopropyl-4-methyl-3-[6-(4-methylpiperazin-1-yl)-4-oxoquinazolin-3(4H)-yl]benzamide (AZD6703), a clinical p38Î± MAP kinase inhibitor for the treatment of inflammatory diseases. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 3879-3883.	1.0	10
439	Modeling the Binding Affinity of p38Î± MAP Kinase Inhibitors by Partial Least Squares Regression. Chemical Biology and Drug Design, 2012, 80, 455-470.	1.5	1
440	Virtual screening filters for the design of type II p38 MAP kinase inhibitors: A fragment based library generation approach. Journal of Molecular Graphics and Modelling, 2012, 34, 89-100.	1.3	31

#	Article	IF	Citations
441	An Accurate Pharmacophore Mapping Method by NMR Spectroscopy. Angewandte Chemie - International Edition, 2012, 51, 1362-1365.	7.2	25
442	Tandem mass spectrometry study of p38Î± kinase inhibitors and related substances. Journal of Mass Spectrometry, 2013, 48, 718-731.	0.7	7
443	An ERK-p38 Subnetwork Coordinates Host Cell Apoptosis and Necrosis during Coxsackievirus B3 Infection. Cell Host and Microbe, 2013, 13, 67-76.	5.1	39
444	Small molecule inhibition of fibroblast growth factor receptors in cancer. Cytokine and Growth Factor Reviews, 2013, 24, 467-475.	3.2	58
445	Contributions of water transfer energy to proteinâ€ligand association and dissociation barriers: Watermap analysis of a series of p38Î± MAP kinase inhibitors. Proteins: Structure, Function and Bioinformatics, 2013, 81, 1509-1526.	1.5	55
446	Conformation-Selective Inhibitors Reveal Differences in the Activation and Phosphate-Binding Loops of the Tyrosine Kinases Abl and Src. ACS Chemical Biology, 2013, 8, 2734-2743.	1.6	30
447	Discovery and characterization of novel allosteric FAK inhibitors. European Journal of Medicinal Chemistry, 2013, 61, 49-60.	2.6	44
448	Type II Kinase Inhibitors: An Opportunity in Cancer for Rational Design. Anti-Cancer Agents in Medicinal Chemistry, 2013, 13, 731-747.	0.9	74
449	<scp>TAK</scp>1 Inhibition in the <scp>DFG</scp>â€Out Conformation. Chemical Biology and Drug Design, 2013, 82, 500-505.	1.5	15
450	Physicochemical properties of the modeled structure of astacin metalloprotease moulting enzyme NAS-36 and mapping the druggable allosteric space of Heamonchus contortus, Brugia malayi and Ceanorhabditis elegans via molecular dynamics simulation. Interdisciplinary Sciences, Computational Life Sciences, 2013, 5, 312-323.	2.2	3
451	Prediction of Ligand-Induced Structural Polymorphism of Receptor Interaction Sites Using Machine Learning. Journal of Chemical Information and Modeling, 2013, 53, 704-716.	2.5	4
452	Intrapulmonary administration of a p38 mitogen activated protein kinase inhibitor partially prevents pulmonary inflammation. Immunobiology, 2013, 218, 435-442.	0.8	1
454	Vinylogous Reactivity of Enol Diazoacetates with Donorâ€“Acceptor Substituted Hydrazones. Synthesis of Substituted Pyrazole Derivatives. Journal of Organic Chemistry, 2013, 78, 1583-1588.	1.7	46
455	A Hexylchloride-Based Catch-and-Release System for Chemical Proteomic Applications. ACS Chemical Biology, 2013, 8, 691-699.	1.6	17
456	Molecular determinants of drugâ€“receptor binding kinetics. Drug Discovery Today, 2013, 18, 667-673.	3.2	307
457	TRAPP: A Tool for Analysis of Transient Binding Pockets in Proteins. Journal of Chemical Information and Modeling, 2013, 53, 1235-1252.	2.5	72
458	Accurate Calculation of Mutational Effects on the Thermodynamics of Inhibitor Binding to p38Î± MAP Kinase: A Combined Computational and Experimental Study. Journal of Chemical Theory and Computation, 2013, 9, 3151-3164.	2.3	18
459	Sequence Determinants of a Specific Inactive Protein Kinase Conformation. Chemistry and Biology, 2013, 20, 806-815.	6.2	77

#	Article	IF	Citations
460	Design, synthesis, and evaluation of novel VEGFR2 kinase inhibitors: Discovery of [1,2,4]triazolo[1,5-a]pyridine derivatives with slow dissociation kinetics. Bioorganic and Medicinal Chemistry, 2013, 21, 4714-4729.	1.4	42
461	Protein Kinase Inhibitor Design by Targeting the Asp-Phe-Gly (DFG) Motif: The Role of the DFG Motif in the Design of Epidermal Growth Factor Receptor Inhibitors. Journal of Medicinal Chemistry, 2013, 56, 3889-3903.	2.9	92
462	Inclusion of Multiple Fragment Types in the Site Identification by Ligand Competitive Saturation (SILCS) Approach. Journal of Chemical Information and Modeling, 2013, 53, 3384-3398.	2.5	101
463	Approaches to discover non-ATP site kinase inhibitors. MedChemComm, 2013, 4, 41-51.	3.5	125
464	Kinase CK2 Inhibition: An Update. Current Medicinal Chemistry, 2013, 20, 671-693.	1.2	94
465	KIDFamMap: a database of kinase-inhibitor-disease family maps for kinase inhibitor selectivity and binding mechanisms. Nucleic Acids Research, 2013, 41, D430-D440.	6.5	23
466	Cycloheximide and lipopolysaccharide downregulate Î±ENaC mRNA via different mechanisms in alveolar epithelial cells. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2013, 305, L747-L755.	1.3	23
467	Differential Roles of CXCL2 and CXCL3 and Their Receptors in Regulating Normal and Asthmatic Airway Smooth Muscle Cell Migration. Journal of Immunology, 2013, 191, 2731-2741.	0.4	110
468	Myocilin Stimulates Osteogenic Differentiation of Mesenchymal Stem Cells through Mitogen-activated Protein Kinase Signaling. Journal of Biological Chemistry, 2013, 288, 16882-16894.	1.6	34
469	Structureâ€“kinetic relationship study of CDK8/CycC specific compounds. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 8081-8086.	3.3	115
470	p38Î± Senses Environmental Stress To Control Innate Immune Responses via Mechanistic Target of Rapamycin. Journal of Immunology, 2013, 190, 1519-1527.	0.4	27
471	BIRB 796 has Distinctive Anti-inflammatory Effects on Different Cell Types. Immune Network, 2013, 13, 283.	1.6	21
473	Altered Regulation of ELAVL1/HuR in HLA-B27â€“Expressing U937 Monocytic Cells. PLoS ONE, 2013, 8, e70377.	1.1	10
474	The Rational Design of Specific Peptide Inhibitor against p38Î± MAPK at Allosteric-Site: A Therapeutic Modality for HNSCC. PLoS ONE, 2014, 9, e101525.	1.1	20
475	Specificity Rendering â€˜Hot-Spotsâ€™ for Aurora Kinase Inhibitor Design: The Role of Non-Covalent Interactions and Conformational Transitions. PLoS ONE, 2014, 9, e113773.	1.1	25
476	Allosteric Modulation. , 2014, , 155-180.		2
477	FLiK. Methods in Enzymology, 2014, 548, 147-171.	0.4	8
478	Novel approaches for targeting kinases: allosteric inhibition, allosteric activation and pseudokinases. Future Medicinal Chemistry, 2014, 6, 541-561.	1.1	80

#	Article	IF	Citations
479	Kinase crystal identification and ATP-competitive inhibitor screening using the fluorescent ligand SKF86002. Acta Crystallographica Section D: Biological Crystallography, 2014, 70, 392-404.	2.5	8
480	Fluorescent biosensors for high throughput screening of protein kinase inhibitors. Biotechnology Journal, 2014, 9, 253-265.	1.8	25
481	Polyphony: superposition independent methods for ensemble-based drug discovery. BMC Bioinformatics, 2014, 15, 324.	1.2	8
482	Structure-Functional Prediction and Analysis of Cancer Mutation Effects in Protein Kinases. Computational and Mathematical Methods in Medicine, 2014, 2014, 1-24.	0.7	30
483	KLIFS: A Knowledge-Based Structural Database To Navigate Kinaseâ€“Ligand Interaction Space. Journal of Medicinal Chemistry, 2014, 57, 249-277.	2.9	243
484	HS-438, a new inhibitor of Imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia. Cancer Letters, 2014, 348, 50-60.	3.2	11
485	Potent and Selective Inhibitors of CDPK1 from T. gondii and C. parvum Based on a 5-Aminopyrazole-4-carboxamide Scaffold. ACS Medicinal Chemistry Letters, 2014, 5, 40-44.	1.3	49
486	Scaffold mining of kinase hinge binders in crystal structure database. Journal of Computer-Aided Molecular Design, 2014, 28, 13-23.	1.3	36
487	Identification of p38Î± MAP kinase inhibitors by pharmacophore based virtual screening. Journal of Molecular Graphics and Modelling, 2014, 49, 18-24.	1.3	20
488	Insight into the Structural Features of Pyrazolopyrimidineâ€•and Pyrazolopyridineâ€based Bâ€Raf^{V600E} Kinase Inhibitors by Computational Explorations. Chemical Biology and Drug Design, 2014, 83, 643-655.	1.5	4
489	Virtual screening and optimization of Type II inhibitors of JAK2 from a natural product library. Chemical Communications, 2014, 50, 13885-13888.	2.2	43
490	Discovery of Novel, Dual Mechanism ERK Inhibitors by Affinity Selection Screening of an Inactive Kinase. Journal of Medicinal Chemistry, 2014, 57, 8817-8826.	2.9	48
491	Exploring Transition Pathway and Free-Energy Profile of Large-Scale Protein Conformational Change by Combining Normal Mode Analysis and Umbrella Sampling Molecular Dynamics. Journal of Physical Chemistry B, 2014, 118, 134-143.	1.2	58
492	Targeting Matrix Metalloproteinases: Exploring the Dynamics of the S1â€² Pocket in the Design of Selective, Small Molecule Inhibitors. Journal of Medicinal Chemistry, 2014, 57, 10205-10219.	2.9	85
493	Synthetic Phosphorylation of p38Î± Recapitulates Protein Kinase Activity. Journal of the American Chemical Society, 2014, 136, 1698-1701.	6.6	46
494	Synthesis of 3-(3-Methyl-1-aryl-1H-pyrazol-5-yl)-2H-2-chromen-2-one Derivatives via a One-Pot, Three-Component Reaction. Synthetic Communications, 2014, 44, 1635-1640.	1.1	8
495	Tropomyosin receptor kinase inhibitors: a patent update 2009 â€“ 2013. Expert Opinion on Therapeutic Patents, 2014, 24, 731-744.	2.4	15
496	Pyrrolo[3,2-b]quinoxaline Derivatives as Types I_{1/2} and II Eph Tyrosine Kinase Inhibitors: Structure-Based Design, Synthesis, and in Vivo Validation. Journal of Medicinal Chemistry, 2014, 57, 6834-6844.	2.9	27

#	Article	IF	Citations
497	A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics. Nature Chemical Biology, 2014, 10, 853-860.	3.9	187
498	Defining a Role for Acid Sphingomyelinase in the p38/Interleukin-6 Pathway. Journal of Biological Chemistry, 2014, 289, 22401-22412.	1.6	22
499	Identification of two novel RET kinase inhibitors through MCR-based drug discovery: Design, synthesis and evaluation. European Journal of Medicinal Chemistry, 2014, 86, 714-723.	2.6	20
500	Presence and utility of intrinsically disordered regions in kinases. Molecular BioSystems, 2014, 10, 2876-2888.	2.9	26
501	BRAF inhibitors: From the laboratory to clinical trials. Critical Reviews in Oncology/Hematology, 2014, 90, 220-232.	2.0	35
502	p38 MAPK inhibitors: a patent review (2012 â€“ 2013). Expert Opinion on Therapeutic Patents, 2014, 24, 535-554.	2.4	53
503	(+)-2-(1-Hydroxyl-4-Oxocyclohexyl) Ethyl Caffeate Suppresses Solar UV-Induced Skin Carcinogenesis by Targeting PI3K, ERK1/2, and p38. Cancer Prevention Research, 2014, 7, 856-865.	0.7	6
504	Crosstalk between mitogen-activated protein kinases and mitochondria in cardiac diseases: Therapeutic perspectives. , 2014, 144, 202-225.		127
505	Bruton's TK inhibitors: structural insights and evolution of clinical candidates. Future Medicinal Chemistry, 2014, 6, 675-695.	1.1	11
506	Identification of Type II and III DDR2 Inhibitors. Journal of Medicinal Chemistry, 2014, 57, 4252-4262.	2.9	34
507	Maximizing Diversity from a Kinase Screen: Identification of Novel and Selective pan-Trk Inhibitors for Chronic Pain. Journal of Medicinal Chemistry, 2014, 57, 5800-5816.	2.9	52
508	Cyclin-Dependent Kinase Inhibitors as Marketed Anticancer Drugs: Where Are We Now? A Short Survey. Molecules, 2014, 19, 14366-14382.	1.7	87
509	Synthesis and Biological Evaluation of Chromenylurea and Chromanylurea Derivatives as Anti-TNF-Î± agents that Target the p38 MAPK Pathway. Molecules, 2014, 19, 2004-2028.	1.7	10
512	Fragmentâ€Based Discovery of a Dual panâ€RET/VEGFR2 Kinase Inhibitor Optimized for Singleâ€Agent Polypharmacology. Angewandte Chemie - International Edition, 2015, 54, 8717-8721.	7.2	33
513	Clinical candidates of small molecule p38 MAPK inhibitors for inflammatory diseases. MAP Kinase, 2015, 4, .	0.3	16
514	Recent Advances in the Development and Application of Radiolabeled Kinase Inhibitors for PET Imaging. Molecules, 2015, 20, 22000-22027.	1.7	25
515	Design, Synthesis and Biological Evaluation of Novel Substituted N,Nâ€²-Diaryl ureas as Potent p38 Inhibitors. Molecules, 2015, 20, 16604-16619.	1.7	1
516	p38Î± MAPK and Type I Inhibitors: Binding Site Analysis and Use of Target Ensembles in Virtual Screening. Molecules, 2015, 20, 15842-15861.	1.7	14

#	Article	IF	Citations
517	Constitutive Activity in an Ancestral Form of Abl Tyrosine Kinase. PLoS ONE, 2015, 10, e0131062.	1.1	8
518	The Anti-Inflammatory Activity of a Novel Fused-Cyclopentenone Phosphonate and Its Potential in the Local Treatment of Experimental Colitis. Gastroenterology Research and Practice, 2015, 2015, 1-10.	0.7	2
519	VS-APPLE: A Virtual Screening Algorithm Using Promiscuous Proteinâ€“Ligand Complexes. Journal of Chemical Information and Modeling, 2015, 55, 1108-1119.	2.5	8
520	Characterization of interactions and pharmacophore development for DFG-out inhibitors to RET tyrosine kinase. Journal of Molecular Modeling, 2015, 21, 167.	0.8	11
521	Anopheles stephensi p38 MAPK signaling regulates innate immunity and bioenergetics during Plasmodium falciparum infection. Parasites and Vectors, 2015, 8, 424.	1.0	18
522	Impact of p38 MAP Kinase Inhibitors on LPS-Induced Release of TNF-Î± in Whole Blood and Primary Cells from Different Species. Cellular Physiology and Biochemistry, 2015, 36, 2237-2249.	1.1	24
523	Structural Analysis of the Binding of Type I, I_{1/2}, and II Inhibitors to Eph Tyrosine Kinases. ACS Medicinal Chemistry Letters, 2015, 6, 79-83.	1.3	9
524	Ten things you should know about protein kinases: <scp>IUPHAR R</scp>eview 14. British Journal of Pharmacology, 2015, 172, 2675-2700.	2.7	270
525	Analyzing Multitarget Activity Landscapes Using Proteinâ€“Ligand Interaction Fingerprints: Interaction Cliffs. Journal of Chemical Information and Modeling, 2015, 55, 251-262.	2.5	23
526	Identification of p38Î² as a Therapeutic Target for the Treatment of SÃ©zary Syndrome. Journal of Investigative Dermatology, 2015, 135, 599-608.	0.3	12
527	The Design of Covalent Allosteric Drugs. Annual Review of Pharmacology and Toxicology, 2015, 55, 249-267.	4.2	96
528	Design strategies to address kinetics of drug binding and residence time. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 2019-2027.	1.0	69
529	Fragment-Based Methods in Drug Discovery. Methods in Molecular Biology, 2015, , .	0.4	6
530	Mechanism of interleukin-13 production by granulocyte-macrophage colony-stimulating factor-dependent macrophages via protease-activated receptor-2. Blood Cells, Molecules, and Diseases, 2015, 55, 21-26.	0.6	22
531	Mechanism of interferon-gamma production by monocytes stimulated with myeloperoxidase and neutrophil extracellular traps. Blood Cells, Molecules, and Diseases, 2015, 55, 127-133.	0.6	17
532	The crystal structure of phosphorylated MAPK13 reveals common structural features and differences in p38 MAPK family activation. Acta Crystallographica Section D: Biological Crystallography, 2015, 71, 790-799.	2.5	31
533	Revealing the favorable dissociation pathway of type II kinase inhibitors via enhanced sampling simulations and two-end-state calculations. Scientific Reports, 2015, 5, 8457.	1.6	72
534	Identification of signalling cascades involved in red blood cell shrinkage and vesiculation. Bioscience Reports, 2015, 35, .	1.1	37

#	Article	IF	Citations
535	Detailed atomistic molecular modeling of a potent type Î™Î™ p38Î± inhibitor. Structural Chemistry, 2015, 26, 1125-1137.	1.0	3
536	Dynamics of Protein Kinases: Insights from Nuclear Magnetic Resonance. Accounts of Chemical Research, 2015, 48, 1106-1114.	7.6	34
537	Hematopoietic stem cell quiescence and function are controlled by the CYLDâ€“TRAF2â€“p38MAPK pathway. Journal of Experimental Medicine, 2015, 212, 525-538.	4.2	46
539	A Proteometric Analysis of Human Kinome: Insight into Discriminant Conformation-dependent Residues. ACS Chemical Biology, 2015, 10, 2827-2840.	1.6	14
540	MEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms. Seminars in Oncology, 2015, 42, 849-862.	0.8	96
541	Structural and dynamic insights into the energetics of activation loop rearrangement in FGFR1 kinase. Nature Communications, 2015, 6, 7877.	5.8	52
542	Recent Advances and New Strategies in Targeting Plk1 for Anticancer Therapy. Trends in Pharmacological Sciences, 2015, 36, 858-877.	4.0	100
543	<scp>p</scp>38 <scp>MAPK</scp> in cardioprotection â€“ are we there yet?. British Journal of Pharmacology, 2015, 172, 2101-2113.	2.7	60
544	On-rate based optimization of structureâ€“kinetic relationship â€“ surfing the kinetic map. Drug Discovery Today: Technologies, 2015, 17, 9-15.	4.0	41
545	Kinase profiling in early stage drug discovery: sorting things out. Drug Discovery Today: Technologies, 2015, 18, 52-61.	4.0	7
546	Synthesis of 5-cyanopyrazolo[1,5-a]pyridine derivatives via tandem reaction and their optical properties. Tetrahedron Letters, 2015, 56, 425-429.	0.7	5
547	Targeting Conformational Plasticity of Protein Kinases. ACS Chemical Biology, 2015, 10, 190-200.	1.6	87
548	Allosteric sites can be identified based on the residue-residue interaction energy difference. Proteins: Structure, Function and Bioinformatics, 2015, 83, 1375-1384.	1.5	17
549	Structural insights into the polypharmacological activity of quercetin on serine/threonine kinases. Drug Design, Development and Therapy, 2016, Volume 10, 3109-3123.	2.0	19
550	Homology Modeling and Ligand-Based Molecule Design. , 2016, , 109-160.		3
551	Synthesis and p38 Inhibitory Activity of Some Novel Substituted N,Nâ€²-Diarylurea Derivatives. Molecules, 2016, 21, 677.	1.7	9
552	Evaluating the Role of p38 MAPK in the Accelerated Cell Senescence of Werner Syndrome Fibroblasts. Pharmaceuticals, 2016, 9, 23.	1.7	18
553	Importance of consensus region of multiple-ligand templates in a virtual screening method. Biophysics and Physicobiology, 2016, 13, 149-156.	0.5	3

#	Article	IF	Citations
554	First comprehensive structural and biophysical analysis of MAPK13 inhibitors targeting DFG-in and DFG-out binding modes. Biochimica Et Biophysica Acta - General Subjects, 2016, 1860, 2335-2344.	1.1	14
555	Allosteric modulators of MEK1: drug design and discovery. Chemical Biology and Drug Design, 2016, 88, 485-497.	1.5	18
556	NMR Characterization of Information Flow and Allosteric Communities in the MAP Kinase p38Î³. Scientific Reports, 2016, 6, 28655.	1.6	19
557	Chemoattractant concentrationâ€“dependent tuning of ERK signaling dynamics in migrating neutrophils. Science Signaling, 2016, 9, ra122.	1.6	26
558	Pyrazolylamine Derivatives Reveal the Conformational Switching between Type I and Type II Binding Modes of Anaplastic Lymphoma Kinase (ALK). Journal of Medicinal Chemistry, 2016, 59, 3906-3919.	2.9	26
559	Conformational Adaption May Explain the Slow Dissociation Kinetics of Roniciclib (BAY 1000394), a Type I CDK Inhibitor with Kinetic Selectivity for CDK2 and CDK9. ACS Chemical Biology, 2016, 11, 1710-1719.	1.6	61
560	Protein Binding Pocket Dynamics. Accounts of Chemical Research, 2016, 49, 809-815.	7.6	268
561	Expression and Purification of EPHA2 Tyrosine Kinase Domain for Crystallographic and NMR Studies. ChemBioChem, 2016, 17, 2257-2263.	1.3	5
562	Development of Specific, Irreversible Inhibitors for a Receptor Tyrosine Kinase EphB3. Journal of the American Chemical Society, 2016, 138, 10554-10560.	6.6	34
563	Considerations of Protein Subpockets in Fragmentâ€Based Drug Design. Chemical Biology and Drug Design, 2016, 87, 5-20.	1.5	13
564	Improved Deconvolution of Protein Targets for Bioactive Compounds Using a Palladium Cleavable Chloroalkane Capture Tag. ACS Chemical Biology, 2016, 11, 2608-2617.	1.6	21
565	Assessment of Hydration Thermodynamics at Protein Interfaces with Grid Cell Theory. Journal of Physical Chemistry B, 2016, 120, 10442-10452.	1.2	11
566	The Discovery of a Potent, Selective, and Peripherally Restricted Pan-Trk Inhibitor (PF-06273340) for the Treatment of Pain. Journal of Medicinal Chemistry, 2016, 59, 10084-10099.	2.9	78
567	Conformational Selection and Induced Fit Mechanisms in the Binding of an Anticancer Drug to the c-Src Kinase. Scientific Reports, 2016, 6, 24439.	1.6	53
568	Dynamic profile analysis to characterize dynamics-driven allosteric sites in enzymes. Biophysics and Physicobiology, 2016, 13, 117-126.	0.5	7
569	Biophysical investigation and conformational analysis of p38Î± kinase inhibitor doramapimod and its analogues. MedChemComm, 2016, 7, 1421-1428.	3.5	4
570	Structural and Functional Analysis of the Allosteric Inhibition of IRE1Î± with ATP-Competitive Ligands. ACS Chemical Biology, 2016, 11, 2195-2205.	1.6	75
571	Discovery of Nonâ€ATPâ€Competitive Inhibitors of Poloâ€like Kinaseâ€...1. ChemMedChem, 2016, 11, 713-717.	1.6	8

#	Article	IF	Citations
572	Three stories on Eph kinase inhibitors: From in silico discovery to inÂvivo validation. European Journal of Medicinal Chemistry, 2016, 112, 347-366.	2.6	24
573	Conformation-Selective Analogues of Dasatinib Reveal Insight into Kinase Inhibitor Binding and Selectivity. ACS Chemical Biology, 2016, 11, 1296-1304.	1.6	58
574	Fluorescence polarization-based assays for detecting compounds binding to inactive c-Jun N-terminal kinase 3 and p38Î± mitogen-activated protein kinase. Analytical Biochemistry, 2016, 503, 28-40.	1.1	22
575	Theoretical Aspects of GPCRâ€“Ligand Complex Pharmacology. Chemical Reviews, 2017, 117, 4-20.	23.0	67
576	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 â€“Part I. Expert Opinion on Therapeutic Patents, 2017, 27, 733-751.	2.4	36
577	Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 â€“ Part II. Expert Opinion on Therapeutic Patents, 2017, 27, 831-849.	2.4	41
578	Dual function of TGFÎ² in lens epithelial cell fate: implications for secondary cataract. Molecular Biology of the Cell, 2017, 28, 907-921.	0.9	39
579	Optimized Target Residence Time: Typeâ€…I Inhibitors for p38Î± MAP Kinase with Improved Binding Kinetics through Direct Interaction with the Râ€šSpine. Angewandte Chemie - International Edition, 2017, 56, 5363-5367.	7.2	20
580	New Challenges in Cancer Therapy: MAPK Inhibitors from Bench to Bedside. , 2017, , 67-91.		1
581	p38 MAPK as an essential regulator of dorsal-ventral axis specification and skeletogenesis during sea urchin development: a re-evaluation. Development (Cambridge), 2017, 144, 2270-2281.	1.2	6
582	Target Residence Time-Guided Optimization on TTK Kinase Results in Inhibitors with Potent Anti-Proliferative Activity. Journal of Molecular Biology, 2017, 429, 2211-2230.	2.0	41
583	Estimation of kinetic and thermodynamic ligand-binding parameters using computational strategies. Future Medicinal Chemistry, 2017, 9, 507-523.	1.1	30
584	Unbinding Kinetics of a p38 MAP Kinase Type II Inhibitor from Metadynamics Simulations. Journal of the American Chemical Society, 2017, 139, 4780-4788.	6.6	187
585	Novel Noncatalytic Substrate-Selective p38Î±-Specific MAPK Inhibitors with Endothelial-Stabilizing and Anti-Inflammatory Activity. Journal of Immunology, 2017, 198, 3296-3306.	0.4	31
586	Identification of a selective inhibitor of transforming growth factor Î²-activated kinase 1 by biosensor-based screening of focused libraries. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 1031-1036.	1.0	1
587	Imidazo[1,2- a]pyridin-6-yl-benzamide analogs as potent RAF inhibitors. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 5221-5224.	1.0	8
588	Challenges and Recent Advances in Medulloblastoma Therapy. Trends in Pharmacological Sciences, 2017, 38, 1061-1084.	4.0	66
589	Design, Synthesis, and Biological Evaluation of Novel Type I¹/₂ p38Î± MAP Kinase Inhibitors with Excellent Selectivity, High Potency, and Prolonged Target Residence Time by Interfering with the R-Spine. Journal of Medicinal Chemistry, 2017, 60, 8027-8054.	2.9	24

#	Article	IF	Citations
590	Oscillatory dynamics of p38 activity with transcriptional and translational time delays. Scientific Reports, 2017, 7, 11495.	1.6	24
591	Anti-inflammatory roles of p38Î± MAPK in macrophages are context dependent and require IL-10. Journal of Leukocyte Biology, 2017, 102, 1219-1227.	1.5	28
593	Glucose impairs aspirin inhibition in platelets through a NAD(P)H oxidase signaling pathway. Prostaglandins and Other Lipid Mediators, 2017, 131, 33-40.	1.0	4
594	Optimierte Bindungsdauer am Zielenzym: Typâ€Iâ€Inhibitoren der p38Î±â€MAPâ€Kinase mit verbesserter Bindungskinetik durch direkte Interaktion mit der Râ€Spine. Angewandte Chemie, 2017, 129, 5448-5453.	1.6	0
595	Classifying kinase conformations using a machine learning approach. BMC Bioinformatics, 2017, 18, 86.	1.2	36
596	Allosteric Drug Effects. , 2017, , 101-129.		2
597	Solvatochromism and linear solvation energy relationship of the kinase inhibitor SKF86002. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2017, 170, 226-233.	2.0	4
598	TRAPP webserver: predicting protein binding site flexibility and detecting transient binding pockets. Nucleic Acids Research, 2017, 45, W325-W330.	6.5	44
599	Protein conformational flexibility modulates kinetics and thermodynamics of drug binding. Nature Communications, 2017, 8, 2276.	5.8	175
600	Structural Hypervariability of the Two Human Protein Kinase CK2 Catalytic Subunit Paralogs Revealed by Complex Structures with a Flavonol- and a Thieno[2,3-d]pyrimidine-Based Inhibitor. Pharmaceuticals, 2017, 10, 9.	1.7	12
601	Medicinal Chemistry Case History: Structure-Based Drug Design of Oral and Inhaled p38 MAP Kinase Inhibitors as Clinical Candidates. , 2017, , 408-430.		0
602	Inflammatory but not mitogenic contexts prime synovial fibroblasts for compensatory signaling responses to p38 inhibition. Science Signaling, 2018, 11, .	1.6	24
603	Halogenâ€“Aromatic Ï€â€…Interactions Modulate Inhibitor Residence Times. Angewandte Chemie - International Edition, 2018, 57, 7220-7224.	7.2	45
604	Mapping the Efficiency and Physicochemical Trajectories of Successful Optimizations. Journal of Medicinal Chemistry, 2018, 61, 6421-6467.	2.9	79
605	Application of singular value decomposition to the inter-fragment interaction energy analysis for ligand screening. Computational and Theoretical Chemistry, 2018, 1132, 23-34.	1.1	22
606	Role of Molecular Interactions and Protein Rearrangement in the Dissociation Kinetics of p38Î± MAP Kinase Type-I/II/III Inhibitors. Journal of Chemical Information and Modeling, 2018, 58, 968-981.	2.5	19
607	A multistep docking and scoring protocol for congeneric series: Implementation on kinase DFG-out type II inhibitors. Future Medicinal Chemistry, 2018, 10, 297-318.	1.1	2
608	Importance of protein flexibility in molecular recognition: a case study on Type-I1/2 inhibitors of ALK. Physical Chemistry Chemical Physics, 2018, 20, 4851-4863.	1.3	22

#	Article	IF	Citations
610	Halogenaromatische Ï€â€¬Wechselwirkungen modulieren die Verweilzeit von Inhibitoren. Angewandte Chemie, 2018, 130, 7338-7343.	1.6	1
611	Exploration and Comparison of the Geometrical and Physicochemical Properties of an Î±C Allosteric Pocket in the Structural Kinome. Journal of Chemical Information and Modeling, 2018, 58, 1094-1103.	2.5	9
612	Fragment-Based Ligand Designing. Methods in Molecular Biology, 2018, 1762, 123-144.	0.4	4
613	Quantitative structure and activity relationship on the biological, nonlinear and the spectroscopic properties of the Schiff base material: 4-chloro-4â€²bromobenzylidene aniline. Molecular Simulation, 2018, 44, 40-54.	0.9	9
614	A Comprehensive Structural Overview of p38Î± Mitogenâ€Activated Protein Kinase in Complex with ATPâ€Site and Nonâ€ATPâ€Site Binders. ChemMedChem, 2018, 13, 7-14.	1.6	20
615	New approaches for computing ligandâ€“receptor binding kinetics. Current Opinion in Structural Biology, 2018, 49, 1-10.	2.6	122
616	Direct monitoring of the conformational equilibria of the activation loop in the mitogen-activated protein kinase p38Î±. Chemical Communications, 2018, 54, 12057-12060.	2.2	10
617	Quantitative conformational profiling of kinase inhibitors reveals origins of selectivity for Aurora kinase activation states. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E11894-E11903.	3.3	52
618	Structureâ€“kinetic relationships that control the residence time of drugâ€“target complexes: insights from molecular structure and dynamics. Current Opinion in Chemical Biology, 2018, 44, 101-109.	2.8	20
619	A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic Screening. Clinical Cancer Research, 2018, 24, 4332-4345.	3.2	154
620	PADFrag: A Database Built for the Exploration of Bioactive Fragment Space for Drug Discovery. Journal of Chemical Information and Modeling, 2018, 58, 1725-1730.	2.5	45
621	Human p38Î± mitogen-activated protein kinase in the Asp168-Phe169-Gly170-in (DFG-in) state can bind allosteric inhibitor Doramapimod. Journal of Biomolecular Structure and Dynamics, 2019, 37, 2049-2060.	2.0	13
622	Structure-Based Virtual Screening of High-Affinity ATP-Competitive Inhibitors Against Human Lemur Tyrosine Kinase-3 (LMTK3) Domain: A Novel Therapeutic Target for Breast Cancer. Interdisciplinary Sciences, Computational Life Sciences, 2019, 11, 527-541.	2.2	10
623	Drug Discovery Targeting Anaplastic Lymphoma Kinase (ALK). Journal of Medicinal Chemistry, 2019, 62, 10927-10954.	2.9	80
624	Repurposing mosloflavone/5,6,7-trimethoxyflavone-resveratrol hybrids: Discovery of novel p38-Î± MAPK inhibitors as potent interceptors of macrophage-dependent production of proinflammatory mediators. European Journal of Medicinal Chemistry, 2019, 180, 253-267.	2.6	38
625	The Discovery of the Nav1.7 Inhibitor GDC-0276 and Development of an Efficient Large-Scale Synthesis. ACS Symposium Series, 2019, , 107-123.	0.5	1
626	Discovery and Development of AMG 333: A TRPM8 Antagonist for Migraine. ACS Symposium Series, 2019, , 125-154.	0.5	1
627	The Discovery and Chemical Development of PF-06273340: A Potent, Selective, and Peripherally Restricted Pan-Trk Inhibitor for Pain. ACS Symposium Series, 2019, , 155-183.	0.5	0

#	Article	IF	Citations
628	Discovery and Development of Non-Covalent, Reversible Brutonâ€™s Tyrosine Kinase Inhibitor Fenebrutinib (GDC-0853). ACS Symposium Series, 2019, , 239-266.	0.5	2
629	Discovery and Early Development of Small Molecule Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors. ACS Symposium Series, 2019, , 267-296.	0.5	0
630	Rational Design to Large-Scale Synthesis: Development of GSK8175 for the Treatment of Hepatitis C Virus Infection. ACS Symposium Series, 2019, , 297-322.	0.5	2
634	Fast Iterative Synthetic Approach toward Identification of Novel Highly Selective p38 MAP Kinase Inhibitors. Journal of Medicinal Chemistry, 2019, 62, 10757-10782.	2.9	18
635	Protein Allostery in Drug Discovery. Advances in Experimental Medicine and Biology, 2019, , .	0.8	11
638	Sustained Egr-1 Response via p38 MAP Kinase Signaling Modulates Early Immune Responses of Dendritic Cells Parasitized by Toxoplasma gondii. Frontiers in Cellular and Infection Microbiology, 2019, 9, 349.	1.8	20
639	Synthetic Routes for Venetoclax at Different Stages of Development. ACS Symposium Series, 2019, , 1-25.	0.5	0
640	Discovery and Development of Lorlatinib: A Macrocyclic Inhibitor of EML4-ALK for the Treatment of NSCLC. ACS Symposium Series, 2019, , 27-59.	0.5	3
641	From Discovery to Market Readiness: The Research and Development of the Î²-Sparing Phosphatidylinositol 3-Kinase Inhibitor Taselisib. ACS Symposium Series, 2019, , 61-83.	0.5	2
642	Optimization of an Azaindazole Series of CCR1 Antagonists and Development of a Semicontinuous-Flow Synthesis. ACS Symposium Series, 2019, , 185-238.	0.5	0
643	Discovery and Development of the First Antibodyâ€“Antibiotic Conjugate Linker-Drug. ACS Symposium Series, 2019, , 85-105.	0.5	2
644	Allosteric small molecule modulators of nuclear receptors. Molecular and Cellular Endocrinology, 2019, 485, 20-34.	1.6	32
645	Impaired circulating myeloid CD1c+ dendritic cell function in human glioblastoma is restored by p38 inhibition â€“ implications for the next generation of DC vaccines. OncoImmunology, 2019, 8, e1593803.	2.1	24
646	Why Some Targets Benefit from beyond Rule of Five Drugs. Journal of Medicinal Chemistry, 2019, 62, 10005-10025.	2.9	75
647	Analysis of tractable allosteric sites in G protein-coupled receptors. Scientific Reports, 2019, 9, 6180.	1.6	31
648	Proteinâ€“ligand interaction fingerprints for accurate prediction of dissociation rates of p38 MAPK Type II inhibitors. Integrative Biology (United Kingdom), 2019, 11, 53-60.	0.6	13
649	Corticosteroids inhibit Mycobacterium tuberculosis-induced necrotic host cell death by abrogating mitochondrial membrane permeability transition. Nature Communications, 2019, 10, 688.	5.8	40
650	Co-crystal structure determination and cellular evaluation of 1,4-dihydropyrazolo[4,3-c] [1,2] benzothiazine 5,5-dioxide p38Î± MAPK inhibitors. Biochemical and Biophysical Research Communications, 2019, 511, 579-586.	1.0	6

#	Article	IF	Citations
651	A Dynamic Switch in Inactive p38Î³ Leads to an Excited State on the Pathway to an Active Kinase. Biochemistry, 2019, 58, 5160-5172.	1.2	7
652	p38Î± Mitogen-Activated Protein Kinase Is a Druggable Target in Pancreatic Adenocarcinoma. Frontiers in Oncology, 2019, 9, 1294.	1.3	20
653	Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application. Journal of Medicinal Chemistry, 2019, 62, 1731-1760.	2.9	58
654	Structural Insights into Characterizing Binding Sites in Epidermal Growth Factor Receptor Kinase Mutants. Journal of Chemical Information and Modeling, 2019, 59, 453-462.	2.5	30
655	Acute inflammation downâ€regulates alphaâ€synuclein expression in enteric neurons. Journal of Neurochemistry, 2019, 148, 746-760.	2.1	20
656	TIPE3 is a regulator of cell apoptosis in glioblastoma. Cancer Letters, 2019, 446, 1-14.	3.2	19
657	Allosteric Modulation. , 2019, , 173-205.		1
658	Discovery of Allosteric, Potent, Subtype Selective, and Peripherally Restricted TrkA Kinase Inhibitors. Journal of Medicinal Chemistry, 2019, 62, 247-265.	2.9	44
659	Sorafenib Activity and Disposition in Liver Cancer Does Not Depend on Organic Cation Transporter 1. Clinical Pharmacology and Therapeutics, 2020, 107, 227-237.	2.3	23
660	Anti-inflammatory effects of a p38 MAP kinase inhibitor, doramapimod, against bacterial cell wall toxins in equine whole blood. Veterinary Immunology and Immunopathology, 2020, 220, 109994.	0.5	1
661	Selective targeting of the Î±C and DFG-out pocket in p38 MAPK. European Journal of Medicinal Chemistry, 2020, 208, 112721.	2.6	12
662	Regulation of Hematopoietic Stem Cell Fate and Malignancy. International Journal of Molecular Sciences, 2020, 21, 4780.	1.8	9
663	Pyrazolyl-Ureas as Interesting Scaffold in Medicinal Chemistry. Molecules, 2020, 25, 3457.	1.7	18
664	Effect of the p38 <scp>MAPK</scp> inhibitor doramapimod on the systemic inflammatory response to intravenous lipopolysaccharide in horses. Journal of Veterinary Internal Medicine, 2020, 34, 2109-2116.	0.6	7
665	PNU-120596, a positive allosteric modulator of Î±7 nicotinic acetylcholine receptor, directly inhibits p38 MAPK. Biochemical Pharmacology, 2020, 182, 114297.	2.0	8
666	The tetraspanin CD151 marks a unique population of activated human T cells. Scientific Reports, 2020, 10, 15748.	1.6	5
667	ToxoplasmaÂ GRA15 and GRA24 are important activators of the host innate immune response in the absence of TLR11. PLoS Pathogens, 2020, 16, e1008586.	2.1	24
668	Conformational selection vs. induced fit: insights into the binding mechanisms of p38Î± MAP Kinase inhibitors. Chemical Communications, 2020, 56, 8818-8821.	2.2	6

#	Article	IF	Citations
669	Druggability Assessment in TRAPP Using Machine Learning Approaches. Journal of Chemical Information and Modeling, 2020, 60, 1685-1699.	2.5	29
670	Protein topology and allostery. Current Opinion in Structural Biology, 2020, 62, 158-165.	2.6	22
671	A post-transcriptional program of chemoresistance by AU-rich elements and TTP in quiescent leukemic cells. Genome Biology, 2020, 21, 33.	3.8	22
673	A precisely positioned MED12 activation helix stimulates CDK8 kinase activity. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 2894-2905.	3.3	47
674	Reveal the interaction mechanism of five old drugs targeting VEGFR2 through computational simulations. Journal of Molecular Graphics and Modelling, 2020, 96, 107538.	1.3	4
675	Bioisosteric Discovery of NPA101.3, a Second-Generation RET/VEGFR2 Inhibitor Optimized for Single-Agent Polypharmacology. Journal of Medicinal Chemistry, 2020, 63, 4506-4516.	2.9	20
676	A novel 20-gene prognostic score in pancreatic adenocarcinoma. PLoS ONE, 2020, 15, e0231835.	1.1	9
677	Rational drug repurposing for cancer by inclusion of the unbiased molecular dynamics simulation in the structure-based virtual screening approach: Challenges and breakthroughs. Seminars in Cancer Biology, 2021, 68, 249-257.	4.3	20
678	Anti-tumor effects and cell motility inhibition of the DN604-gemcitabine combined treatment in human bladder cancer models. Bioorganic and Medicinal Chemistry, 2021, 29, 115858.	1.4	2
679	Candidate Binding Sites for Allosteric Inhibition of the SARS-CoV-2 Main Protease from the Analysis of Large-Scale Molecular Dynamics Simulations. Journal of Physical Chemistry Letters, 2021, 12, 65-72.	2.1	18
680	Deciphering molecular mechanism behind conformational change of the SÃ£o Paolo metallo-Î²-lactamase 1 by using enhanced sampling. Journal of Biomolecular Structure and Dynamics, 2021, 39, 140-151.	2.0	8
681	The development of an Amber-compatible organosilane force field for drug-like small molecules. Physical Chemistry Chemical Physics, 2021, 23, 12582-12591.	1.3	10
682	HISNAPI: a bioinformatic tool for dynamic hot spot analysis in nucleic acidâ€“protein interface with a case study. Briefings in Bioinformatics, 2021, 22, .	3.2	8
683	Potential Allosteric Sites Captured in Glycolytic Enzymes Via Residue-Based Network Models: Phosphofructokinase, Glyceraldehyde-3-Phosphate Dehydrogenase and Pyruvate Kinase. SSRN Electronic Journal, 0, , .	0.4	0
684	Protein Structure, Dynamics and Assembly: Implications for Drug Discovery. , 2021, , 91-122.		1
685	Structure-Based Design of Potent Selective Nanomolar Type-II Inhibitors of Glycogen Synthase Kinase-3Î². Journal of Medicinal Chemistry, 2021, 64, 1497-1509.	2.9	9
686	Design and development of a photoswitchable DFG-out kinase inhibitor. Chemical Communications, 2021, 57, 10043-10046.	2.2	9
687	Activated microgliaâ€“induced neuroinflammatory cytokines lead to photoreceptor apoptosis in AÎ²-injected mice. Journal of Molecular Medicine, 2021, 99, 713-728.	1.7	8

#	Article	IF	Citations
689	Current status and future prospects of p38Î±/MAPK14 kinase and its inhibitors. European Journal of Medicinal Chemistry, 2021, 213, 113216.	2.6	45
690	DeepDTAF: a deep learning method to predict proteinâ€“ligand binding affinity. Briefings in Bioinformatics, 2021, 22, .	3.2	61
691	BIRB796, an Inhibitor of p38 Mitogen-Activated Protein Kinase, Inhibits Proliferation and Invasion in Glioblastoma Cells. ACS Omega, 2021, 6, 11466-11473.	1.6	7
692	A Special View of What Was Almost Forgotten: p38Î´ MAPK. Cancers, 2021, 13, 2077.	1.7	10
693	Design and synthesis of Î²-carboline and combretastatin derivatives as anti-neutrophilic inflammatory agents. Bioorganic Chemistry, 2021, 111, 104846.	2.0	4
694	Validation of ion mobility spectrometry â€•mass spectrometry as a screening tool to identify type II kinase inhibitors of FGFR1 kinase. Rapid Communications in Mass Spectrometry, 2021, , e9130.	0.7	4
695	Prediction of the Drugâ€“Target Binding Kinetics for Flexible Proteins by Comparative Binding Energy Analysis. Journal of Chemical Information and Modeling, 2021, 61, 3708-3721.	2.5	12
696	Current Insights and Advancements in Head and Neck Cancer: Emerging Biomarkers and Therapeutics with Cues from Single Cell and 3D Model Omics Profiling. Frontiers in Oncology, 2021, 11, 676948.	1.3	5
699	Structure-Based Drug Design. Biological and Medical Physics Series, 2007, , 135-176.	0.3	3
700	Designing an Orally Available Nontoxic p38 Inhibitor with a Fragment-Based Strategy. Methods in Molecular Biology, 2015, 1289, 211-226.	0.4	7
701	Use of Inhibitors in the Study of MAP Kinases. Methods in Molecular Biology, 2010, 661, 107-122.	0.4	22
702	The Design, Annotation, and Application of a Kinase-Targeted Library. Methods in Molecular Biology, 2011, 685, 279-291.	0.4	11
703	Small-Molecule Protein and Lipid Kinase Inhibitors in Inflammation and Specific Models for Their Evaluation. Methods in Molecular Biology, 2012, 795, 35-44.	0.4	1
704	Fluorescence Labels in Kinases: A High-Throughput Kinase Binding Assay for the Identification of DFG-Out Binding Ligands. Methods in Molecular Biology, 2012, 800, 95-117.	0.4	2
705	Structural Biology Contributions to the Discovery of Drugs to Treat Chronic Myelogenous Leukemia. NATO Science for Peace and Security Series A: Chemistry and Biology, 2009, , 37-61.	0.5	2
706	Allosteric Small-Molecule Serine/Threonine Kinase Inhibitors. Advances in Experimental Medicine and Biology, 2019, 1163, 253-278.	0.8	18
707	p38 gamma MAP kinase. The AFCS-nature Molecule Pages, 0, , .	0.2	16
708	Mechanistic enzymology in drug discovery: a fresh perspective. Nature Reviews Drug Discovery, 2018, 17, 115-132.	21.5	124

#	Article	IF	Citations
709	Of Mice and Monkeys: Neuroprotective Efficacy of the p38 Inhibitor BIRB 796 Depends on Model Duration in Experimental Glaucoma. Scientific Reports, 2020, 10, 8535.	1.6	14
710	CHAPTER 3. Targeting Catalytic and Non-Catalytic Functions of Protein Kinases. , 0, , 40-64.		1
711	Novel p38Î± MAP kinase inhibitors identified from yoctoReactor DNA-encoded small molecule library. MedChemComm, 2016, 7, 1332-1339.	3.5	68
713	IL-13â€“induced airway mucus production is attenuated by MAPK13 inhibition. Journal of Clinical Investigation, 2012, 122, 4555-4568.	3.9	168
715	Crystal Structures of the FAK Kinase in Complex with TAE226 and Related Bis-Anilino Pyrimidine Inhibitors Reveal a Helical DFG Conformation. PLoS ONE, 2008, 3, e3800.	1.1	87
716	Binding-Site Assessment by Virtual Fragment Screening. PLoS ONE, 2010, 5, e10109.	1.1	56
717	BIRB796, the Inhibitor of p38 Mitogen-Activated Protein Kinase, Enhances the Efficacy of Chemotherapeutic Agents in ABCB1 Overexpression Cells. PLoS ONE, 2013, 8, e54181.	1.1	22
718	Osmostress enhances activating phosphorylation of Hog1 <scp>MAP</scp> kinase by monoâ€phosphorylated Pbs2 <scp>MAP</scp> 2K. EMBO Journal, 2020, 39, e103444.	3.5	44
719	Targeting Mnks for Cancer Therapy. Oncotarget, 2012, 3, 118-131.	0.8	132
720	From Small to Powerful: The Fragments Universe and its “Chem-Appeal”. Current Medicinal Chemistry, 2013, 20, 1355-1381.	1.2	17
721	Pharmacophore and Binding Analysis of Known and Novel B-RAF Kinase Inhibitors. Current Medicinal Chemistry, 2014, 21, 1938-1955.	1.2	6
722	Carbazole Derivatives as Kinase-Targeting Inhibitors for Cancer Treatment. Mini-Reviews in Medicinal Chemistry, 2020, 20, 444-465.	1.1	12
723	Current Insights of Inhibitors of p38 Mitogen-Activated Protein Kinase in Inflammation. Medicinal Chemistry, 2021, 17, 555-575.	0.7	20
724	Study of Functional and Allosteric Sites in Protein Superfamilies. Acta Naturae, 2015, 7, 34-45.	1.7	19
725	Theoretical Characterization of Binding Mode of Organosilicon Inhibitor with p38: Docking, MD Simulation and MM/GBSA Free Energy Approach. Bulletin of the Korean Chemical Society, 2014, 35, 2494-2504.	1.0	1
726	Identification of Diarylurea Inhibitors of the Cardiac-Specific Kinase TNNI3K by Designing Selectivity Against VEGFR2, p38Î±, and B-Raf. Journal of Medicinal Chemistry, 2021, 64, 15651-15670.	2.9	6
727	Anti-Hepatocellular Carcinoma Biomolecules: Molecular Targets Insights. International Journal of Molecular Sciences, 2021, 22, 10774.	1.8	64
733	2-tert-butyl-1,4-benzoquinone Induces Apoptosis in Chronic Myeloid Leukemia Cells Resistant to Imatinib via Inducing Caspase-Dependent Bcr- Abl Downregulation. , 0, , .		0

#	Article	IF	Citations
734	Virtual Fragment Preparation for Computational Fragment-Based Drug Design. Methods in Molecular Biology, 2015, 1289, 31-41.	0.4	0
740	A rapid strategy for screening high-efficiency PCSK9 inhibitors from Ginkgo biloba leaves by ligand fishing, HPLC-Q-TOF-MS and interdisciplinary assay. Journal of Food and Drug Analysis, 2020, 28, 273-282.	0.9	0
742	Potential allosteric sites captured in glycolytic enzymes via residue-based network models: Phosphofructokinase, glyceraldehyde-3-phosphate dehydrogenase and pyruvate kinase. Biophysical Chemistry, 2022, 280, 106701.	1.5	5
743	Understanding the mechanism of action of pyrrolo[3,2-b]quinoxaline-derivatives as kinase inhibitors. RSC Medicinal Chemistry, 2020, 11, 665-675.	1.7	4
745	Fragment-Based Screening by X-ray Crystallography. , 2007, , 99-127.		0
748	Study of Functional and Allosteric Sites in Protein Superfamilies. Acta Naturae, 2015, 7, 34-45.	1.7	8
749	Pharmacologic profiling reveals lapatinib as a novel antiviral against SARS-CoV-2 in vitro. Virology, 2022, 566, 60-68.	1.1	19
750	Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent Resistance. Molecular Cancer Therapeutics, 2022, 21, 322-335.	1.9	10
751	Resistance to kinase inhibition through shortened target engagement. Molecular and Cellular Oncology, 2022, 9, 2029999.	0.3	1
752	Tracking protein domain movements by EPR distance determination and multilateration. Methods in Enzymology, 2022, 666, 121-144.	0.4	2
753	Risk score model of autophagy-related genes in osteosarcoma. Annals of Translational Medicine, 2022, 10, 252-252.	0.7	1
754	Endoderm development requires centrioles to restrain p53-mediated apoptosis in the absence of ERK activity. Developmental Cell, 2021, 56, 3334-3348.e6.	3.1	9
755	PHA-680626 Is an Effective Inhibitor of the Interaction between Aurora-A and N-Myc. International Journal of Molecular Sciences, 2021, 22, 13122.	1.8	8
756	p38 regulates the tumor suppressor PDCD4 via the TSC-mTORC1 pathway. Cell Stress, 2021, 5, 176-182.	1.4	4
757	Impact and Evolution of Biophysics in Medicinal Chemistry. RSC Drug Discovery Series, 2017, , 1-22.	0.2	0
770	Chemical Biology of Kinases Studied by NMR Spectroscopy. , 0, , 852-890.		1
771	Expedient Access to Type II Kinase Inhibitor Chemotypes by Microwave-Assisted Suzuki Coupling. , 2022, 1, 64-72.		2
772	p38 MAPK Is a Major Regulator of Amyloid Beta-Induced IL-6 Expression in Human Microglia. Molecular Neurobiology, 2022, 59, 5284-5298.	1.9	7

#	Article	IF	Citations
773	Genkwanin Prevents Lipopolysaccharide-Induced Inflammatory Bone Destruction and Ovariectomy-Induced Bone Loss. Frontiers in Nutrition, 0, 9, .	1.6	3
775	Integration of In Silico Strategies for Drug Repositioning towards P38Î± Mitogen-Activated Protein Kinase (MAPK) at the Allosteric Site. Pharmaceutics, 2022, 14, 1461.	2.0	5
776	New fluorinated diarylureas linked to pyrrolo[2,3-d]pyrimidine scaffold as VEGFR-2 inhibitors: Molecular docking and biological evaluation. Bioorganic Chemistry, 2022, 127, 106006.	2.0	4
777	Mutagenic Activation of Glutathione Peroxidase-4: Approaches toward Rational Design of Allosteric Drugs. ACS Omega, 0, , .	1.6	3
778	Allosteric modulation. , 2022, , 233-267.		0
780	High-throughput screen to identify compounds that prevent or target telomere loss in human cancer cells. NAR Cancer, 2022, 4, .	1.6	0
781	Investigation of structureâ€“activity relationship: In silico studies of [1, 2, 4]triazolo[4, 3-a]pyridine ureas as P38 kinase inhibitors. Structural Chemistry, 0, , .	1.0	0
782	p38MAPK guards the integrity of endosomal compartments through regulating necrotic death. Scientific Reports, 2022, 12, .	1.6	1
783	Immune depletion of the methylated phenotype of colon cancer is closely related to resistance to immune checkpoint inhibitors. Frontiers in Immunology, 0, 13, .	2.2	2
784	Protective effect of genkwanin against lipopolysaccharide-induced acute lung injury in mice with p38 mitogen-activated protein kinase and nuclear factor-ÎºB pathway inhibition. Journal of Functional Foods, 2022, 98, 105271.	1.6	3
785	Predictive functional, statistical and structural analysis of CSNK2A1 and CSNK2B variants linked to neurodevelopmental diseases. Frontiers in Molecular Biosciences, 0, 9, .	1.6	2
786	Silver-catalysed [3 + 2] annulation reaction of aryldiazonium salts with allenes enabled by boronate direction. Organic Chemistry Frontiers, 2022, 10, 74-82.	2.3	2
787	Evolutionary divergence in the conformational landscapes of tyrosine vs serine/threonine kinases. ELife, 0, 11, .	2.8	7
788	Identification of Covalent Ligands â€“ from Single Targets to Whole Proteome. Israel Journal of Chemistry, 2023, 63, .	1.0	0
789	In vitro and in silico studies of 7â€²â€²,8â€²â€²-buddlenol D anti-inflammatory lignans from Carallia brachiata as p38 MAP kinase inhibitors. Scientific Reports, 2023, 13, .	1.6	3
790	Cadmium-induced Sertoli Cell Injury Through p38-MAPK and Related Signaling Proteinsâ€”A Study by RNA Sequencing. Endocrinology, 2023, 164, .	1.4	3
791	2â€²Phenylquinazolinâ€4(3H)â€one scaffold as newly designed, synthesized VEGFRâ€2 allosteric inhibitors with potent cytotoxicity through apoptosis. Archiv Der Pharmazie, 2023, 356, .	2.1	2
792	A Review On Inhibitory Action of Tyrosine Kinase Inhibitors (TKI) by Curbing the ATP-Tyrosine Kinase Interactions. Current Signal Transduction Therapy, 2023, 18, .	0.3	0

#	Article	IF	Citations
793	In Vitro Biology: Measuring Pharmacological Activity that Will Translate to Clinical Efficacy. , 2023, , 402-436.		0
807	Growth factors reviews. , 2024, , 19-112.		0